WO2008038010A1 - Pyrazine derivatives and their use in therapy - Google Patents
Pyrazine derivatives and their use in therapy Download PDFInfo
- Publication number
- WO2008038010A1 WO2008038010A1 PCT/GB2007/003687 GB2007003687W WO2008038010A1 WO 2008038010 A1 WO2008038010 A1 WO 2008038010A1 GB 2007003687 W GB2007003687 W GB 2007003687W WO 2008038010 A1 WO2008038010 A1 WO 2008038010A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- compound
- alkyl
- hydroxy
- piperidin
- hydrogen
- Prior art date
Links
- 238000002560 therapeutic procedure Methods 0.000 title abstract description 6
- 150000003216 pyrazines Chemical class 0.000 title description 4
- 150000001875 compounds Chemical class 0.000 claims abstract description 101
- 125000000217 alkyl group Chemical group 0.000 claims abstract description 58
- 229910052739 hydrogen Inorganic materials 0.000 claims abstract description 54
- 239000001257 hydrogen Substances 0.000 claims abstract description 48
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims abstract description 37
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims abstract description 21
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 claims abstract description 17
- 125000001153 fluoro group Chemical group F* 0.000 claims abstract description 17
- 238000011282 treatment Methods 0.000 claims abstract description 15
- 150000003839 salts Chemical class 0.000 claims abstract description 13
- 125000005843 halogen group Chemical group 0.000 claims abstract description 12
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims abstract description 11
- 230000005764 inhibitory process Effects 0.000 claims abstract description 10
- 125000006274 (C1-C3)alkoxy group Chemical group 0.000 claims abstract description 8
- 125000001072 heteroaryl group Chemical group 0.000 claims abstract description 7
- 125000003118 aryl group Chemical group 0.000 claims abstract description 6
- 239000012453 solvate Substances 0.000 claims abstract description 5
- -1 -C(=O)OH Chemical group 0.000 claims description 73
- 238000000034 method Methods 0.000 claims description 36
- 229910052757 nitrogen Inorganic materials 0.000 claims description 32
- 239000000203 mixture Substances 0.000 claims description 26
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 26
- 102000003989 Aurora kinases Human genes 0.000 claims description 16
- 108090000433 Aurora kinases Proteins 0.000 claims description 16
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 15
- 230000000694 effects Effects 0.000 claims description 12
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 11
- 206010028980 Neoplasm Diseases 0.000 claims description 11
- 125000000954 2-hydroxyethyl group Chemical group [H]C([*])([H])C([H])([H])O[H] 0.000 claims description 10
- 125000004070 6 membered heterocyclic group Chemical group 0.000 claims description 10
- 125000003545 alkoxy group Chemical group 0.000 claims description 8
- 201000011510 cancer Diseases 0.000 claims description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 8
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 8
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 claims description 6
- 125000003386 piperidinyl group Chemical group 0.000 claims description 6
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims description 5
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims description 5
- 241000124008 Mammalia Species 0.000 claims description 5
- 125000000587 piperidin-1-yl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 claims description 5
- 238000002360 preparation method Methods 0.000 claims description 5
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 5
- 125000004200 2-methoxyethyl group Chemical group [H]C([H])([H])OC([H])([H])C([H])([H])* 0.000 claims description 4
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims description 4
- 201000010099 disease Diseases 0.000 claims description 4
- 125000002757 morpholinyl group Chemical group 0.000 claims description 4
- 125000004076 pyridyl group Chemical group 0.000 claims description 4
- 125000000719 pyrrolidinyl group Chemical group 0.000 claims description 4
- 125000004206 2,2,2-trifluoroethyl group Chemical group [H]C([H])(*)C(F)(F)F 0.000 claims description 3
- 125000004215 2,4-difluorophenyl group Chemical group [H]C1=C([H])C(*)=C(F)C([H])=C1F 0.000 claims description 3
- 125000004198 2-fluorophenyl group Chemical group [H]C1=C([H])C(F)=C(*)C([H])=C1[H] 0.000 claims description 3
- 125000004211 3,5-difluorophenyl group Chemical group [H]C1=C(F)C([H])=C(*)C([H])=C1F 0.000 claims description 3
- 125000004179 3-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(Cl)=C1[H] 0.000 claims description 3
- 125000004180 3-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(F)=C1[H] 0.000 claims description 3
- 125000000040 m-tolyl group Chemical group [H]C1=C([H])C(*)=C([H])C(=C1[H])C([H])([H])[H] 0.000 claims description 3
- 125000004193 piperazinyl group Chemical group 0.000 claims description 3
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims description 2
- 206010005003 Bladder cancer Diseases 0.000 claims description 2
- 206010006187 Breast cancer Diseases 0.000 claims description 2
- 208000026310 Breast neoplasm Diseases 0.000 claims description 2
- 206010009944 Colon cancer Diseases 0.000 claims description 2
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims description 2
- 208000008839 Kidney Neoplasms Diseases 0.000 claims description 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 2
- 206010025323 Lymphomas Diseases 0.000 claims description 2
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 2
- 206010060862 Prostate cancer Diseases 0.000 claims description 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 2
- 206010038389 Renal cancer Diseases 0.000 claims description 2
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims description 2
- 210000000481 breast Anatomy 0.000 claims description 2
- 230000003463 hyperproliferative effect Effects 0.000 claims description 2
- 201000010982 kidney cancer Diseases 0.000 claims description 2
- 208000032839 leukemia Diseases 0.000 claims description 2
- 210000004072 lung Anatomy 0.000 claims description 2
- 201000005202 lung cancer Diseases 0.000 claims description 2
- 208000020816 lung neoplasm Diseases 0.000 claims description 2
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 2
- 201000002528 pancreatic cancer Diseases 0.000 claims description 2
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims description 2
- 210000002307 prostate Anatomy 0.000 claims description 2
- 210000003932 urinary bladder Anatomy 0.000 claims description 2
- 201000005112 urinary bladder cancer Diseases 0.000 claims description 2
- 125000004356 hydroxy functional group Chemical group O* 0.000 claims 11
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 claims 2
- 125000004486 1-methylpiperidin-3-yl group Chemical group CN1CC(CCC1)* 0.000 claims 1
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 claims 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract description 15
- 108090000461 Aurora Kinase A Proteins 0.000 abstract description 3
- 108090000749 Aurora kinase B Proteins 0.000 abstract description 3
- 102100032311 Aurora kinase A Human genes 0.000 abstract 1
- 102100032306 Aurora kinase B Human genes 0.000 abstract 1
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 48
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 35
- 210000004027 cell Anatomy 0.000 description 32
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 22
- 239000007787 solid Substances 0.000 description 21
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 15
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 14
- 239000011541 reaction mixture Substances 0.000 description 14
- 235000019439 ethyl acetate Nutrition 0.000 description 13
- 150000003254 radicals Chemical class 0.000 description 13
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 12
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 12
- 230000015572 biosynthetic process Effects 0.000 description 12
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 12
- 238000003786 synthesis reaction Methods 0.000 description 12
- 239000005441 aurora Substances 0.000 description 11
- 239000003112 inhibitor Substances 0.000 description 11
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 10
- 238000003556 assay Methods 0.000 description 10
- 239000000377 silicon dioxide Substances 0.000 description 10
- 239000012267 brine Substances 0.000 description 9
- 238000003818 flash chromatography Methods 0.000 description 9
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 9
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 8
- 108090000765 processed proteins & peptides Proteins 0.000 description 8
- 239000000243 solution Substances 0.000 description 8
- 125000001424 substituent group Chemical group 0.000 description 8
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 7
- 239000003814 drug Substances 0.000 description 7
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 7
- 239000000651 prodrug Substances 0.000 description 7
- 229940002612 prodrug Drugs 0.000 description 7
- 239000002904 solvent Substances 0.000 description 7
- 239000000725 suspension Substances 0.000 description 7
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 6
- 238000000684 flow cytometry Methods 0.000 description 6
- 235000019253 formic acid Nutrition 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 5
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 5
- 238000006243 chemical reaction Methods 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 238000009472 formulation Methods 0.000 description 5
- 125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 description 5
- 238000005160 1H NMR spectroscopy Methods 0.000 description 4
- 108091000080 Phosphotransferase Proteins 0.000 description 4
- 238000007792 addition Methods 0.000 description 4
- 208000035475 disorder Diseases 0.000 description 4
- 238000001914 filtration Methods 0.000 description 4
- 125000000623 heterocyclic group Chemical group 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- NUJOXMJBOLGQSY-UHFFFAOYSA-N manganese dioxide Chemical compound O=[Mn]=O NUJOXMJBOLGQSY-UHFFFAOYSA-N 0.000 description 4
- 238000004949 mass spectrometry Methods 0.000 description 4
- 102000020233 phosphotransferase Human genes 0.000 description 4
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 4
- XJMOSONTPMZWPB-UHFFFAOYSA-M propidium iodide Chemical compound [I-].[I-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CCC[N+](C)(CC)CC)=C1C1=CC=CC=C1 XJMOSONTPMZWPB-UHFFFAOYSA-M 0.000 description 4
- 239000006188 syrup Substances 0.000 description 4
- 235000020357 syrup Nutrition 0.000 description 4
- 239000003981 vehicle Substances 0.000 description 4
- YYXOCHWGFKAGCH-UHFFFAOYSA-N 3,4-diamino-n-(3-fluorophenyl)benzamide Chemical compound C1=C(N)C(N)=CC=C1C(=O)NC1=CC=CC(F)=C1 YYXOCHWGFKAGCH-UHFFFAOYSA-N 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 3
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- 125000004432 carbon atom Chemical group C* 0.000 description 3
- 239000003054 catalyst Substances 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- WHQLQYRFIHPMNA-UHFFFAOYSA-N ethyl acetate;oxolane Chemical compound C1CCOC1.CCOC(C)=O WHQLQYRFIHPMNA-UHFFFAOYSA-N 0.000 description 3
- 125000005842 heteroatom Chemical group 0.000 description 3
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 150000002500 ions Chemical class 0.000 description 3
- 125000000842 isoxazolyl group Chemical group 0.000 description 3
- 230000001404 mediated effect Effects 0.000 description 3
- 239000000600 sorbitol Substances 0.000 description 3
- 235000010356 sorbitol Nutrition 0.000 description 3
- 239000003826 tablet Substances 0.000 description 3
- 239000003643 water by type Substances 0.000 description 3
- VJLLCUVQAVXGJG-UHFFFAOYSA-N 2-[3-amino-6-(3-formylphenyl)pyrazin-2-yl]-n-(3-fluorophenyl)-3h-benzimidazole-5-carboxamide Chemical compound NC1=NC=C(C=2C=C(C=O)C=CC=2)N=C1C(NC1=C2)=NC1=CC=C2C(=O)NC1=CC=CC(F)=C1 VJLLCUVQAVXGJG-UHFFFAOYSA-N 0.000 description 2
- JANCWUGKJHVZPD-UHFFFAOYSA-N 2-[3-amino-6-[3-(2-hydroxyethyl)phenyl]pyrazin-2-yl]-n-(3-fluorophenyl)-3h-benzimidazole-5-carboxamide Chemical compound NC1=NC=C(C=2C=C(CCO)C=CC=2)N=C1C(NC1=C2)=NC1=CC=C2C(=O)NC1=CC=CC(F)=C1 JANCWUGKJHVZPD-UHFFFAOYSA-N 0.000 description 2
- XNEVPBIXXTYRTI-UHFFFAOYSA-N 2-[3-amino-6-[3-[2-[ethyl(2-hydroxyethyl)amino]ethyl]phenyl]pyrazin-2-yl]-n-(3-fluorophenyl)-3h-benzimidazole-5-carboxamide Chemical compound OCCN(CC)CCC1=CC=CC(C=2N=C(C(N)=NC=2)C=2NC3=CC(=CC=C3N=2)C(=O)NC=2C=C(F)C=CC=2)=C1 XNEVPBIXXTYRTI-UHFFFAOYSA-N 0.000 description 2
- UWAARASVHMVQLC-UHFFFAOYSA-N 2-[3-amino-6-[3-[[ethyl(2-hydroxyethyl)amino]methyl]phenyl]pyrazin-2-yl]-n-(3-fluorophenyl)-3h-benzimidazole-5-carboxamide Chemical compound OCCN(CC)CC1=CC=CC(C=2N=C(C(N)=NC=2)C=2NC3=CC(=CC=C3N=2)C(=O)NC=2C=C(F)C=CC=2)=C1 UWAARASVHMVQLC-UHFFFAOYSA-N 0.000 description 2
- QZVQQUVWFIZUBQ-UHFFFAOYSA-N 3-fluoroaniline Chemical compound NC1=CC=CC(F)=C1 QZVQQUVWFIZUBQ-UHFFFAOYSA-N 0.000 description 2
- 102000004000 Aurora Kinase A Human genes 0.000 description 2
- 102000004228 Aurora kinase B Human genes 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 2
- 240000007472 Leucaena leucocephala Species 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 2
- WPWVFPOXASEVKO-UHFFFAOYSA-N NC=1C(=NC(=CN1)C1=CC(=CC=C1)C(O[SiH2]C(C)(C)C)(C)C)C=O Chemical compound NC=1C(=NC(=CN1)C1=CC(=CC=C1)C(O[SiH2]C(C)(C)C)(C)C)C=O WPWVFPOXASEVKO-UHFFFAOYSA-N 0.000 description 2
- DWAQJAXMDSEUJJ-UHFFFAOYSA-M Sodium bisulfite Chemical compound [Na+].OS([O-])=O DWAQJAXMDSEUJJ-UHFFFAOYSA-M 0.000 description 2
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 239000002585 base Substances 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 230000003197 catalytic effect Effects 0.000 description 2
- 230000022131 cell cycle Effects 0.000 description 2
- 230000032823 cell division Effects 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 239000006071 cream Substances 0.000 description 2
- 125000000753 cycloalkyl group Chemical group 0.000 description 2
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N diphenyl Chemical compound C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 description 2
- 235000019441 ethanol Nutrition 0.000 description 2
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 2
- 125000002541 furyl group Chemical group 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 125000002883 imidazolyl group Chemical group 0.000 description 2
- 125000001041 indolyl group Chemical group 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 2
- 125000001786 isothiazolyl group Chemical group 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 239000002207 metabolite Substances 0.000 description 2
- MGYBQZMZRXOEJA-UHFFFAOYSA-N methyl 3-amino-6-[3-[[tert-butyl(dimethyl)silyl]oxymethyl]phenyl]pyrazine-2-carboxylate Chemical compound N1=C(N)C(C(=O)OC)=NC(C=2C=C(CO[Si](C)(C)C(C)(C)C)C=CC=2)=C1 MGYBQZMZRXOEJA-UHFFFAOYSA-N 0.000 description 2
- 230000011278 mitosis Effects 0.000 description 2
- 230000000394 mitotic effect Effects 0.000 description 2
- 238000012544 monitoring process Methods 0.000 description 2
- CKMGFVNIJGVDDQ-UHFFFAOYSA-N n-(3-fluorophenyl)-3,4-dinitrobenzamide Chemical compound C1=C([N+]([O-])=O)C([N+](=O)[O-])=CC=C1C(=O)NC1=CC=CC(F)=C1 CKMGFVNIJGVDDQ-UHFFFAOYSA-N 0.000 description 2
- 239000002674 ointment Substances 0.000 description 2
- 125000002971 oxazolyl group Chemical group 0.000 description 2
- 230000026731 phosphorylation Effects 0.000 description 2
- 238000006366 phosphorylation reaction Methods 0.000 description 2
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 2
- 229910000027 potassium carbonate Inorganic materials 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 125000003226 pyrazolyl group Chemical group 0.000 description 2
- 125000000714 pyrimidinyl group Chemical group 0.000 description 2
- 125000000168 pyrrolyl group Chemical group 0.000 description 2
- 238000012552 review Methods 0.000 description 2
- 125000000467 secondary amino group Chemical group [H]N([*:1])[*:2] 0.000 description 2
- 239000004289 sodium hydrogen sulphite Substances 0.000 description 2
- 235000010267 sodium hydrogen sulphite Nutrition 0.000 description 2
- 235000011121 sodium hydroxide Nutrition 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 229910052717 sulfur Inorganic materials 0.000 description 2
- 125000001113 thiadiazolyl group Chemical group 0.000 description 2
- 125000000335 thiazolyl group Chemical group 0.000 description 2
- 125000001544 thienyl group Chemical group 0.000 description 2
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 2
- 230000000699 topical effect Effects 0.000 description 2
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 description 2
- 238000000825 ultraviolet detection Methods 0.000 description 2
- MKWJZTFMDWSRIH-UHFFFAOYSA-N (4-fluoro-3-nitrophenyl)methanol Chemical compound OCC1=CC=C(F)C([N+]([O-])=O)=C1 MKWJZTFMDWSRIH-UHFFFAOYSA-N 0.000 description 1
- DAXJNUBSBFUTRP-RTQNCGMRSA-N (8r,9s,10r,13s,14s)-6-(hydroxymethyl)-10,13-dimethyl-7,8,9,11,12,14,15,16-octahydro-6h-cyclopenta[a]phenanthrene-3,17-dione Chemical compound O=C1C=C[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CC(CO)C2=C1 DAXJNUBSBFUTRP-RTQNCGMRSA-N 0.000 description 1
- ZORQXIQZAOLNGE-UHFFFAOYSA-N 1,1-difluorocyclohexane Chemical compound FC1(F)CCCCC1 ZORQXIQZAOLNGE-UHFFFAOYSA-N 0.000 description 1
- LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide Substances CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- IEQAICDLOKRSRL-UHFFFAOYSA-N 2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-(2-dodecoxyethoxy)ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethanol Chemical compound CCCCCCCCCCCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO IEQAICDLOKRSRL-UHFFFAOYSA-N 0.000 description 1
- LIDKMOSULRVJAY-UHFFFAOYSA-N 2-[3-amino-6-[3-[2-[3-(hydroxymethyl)piperidin-1-yl]ethyl]phenyl]pyrazin-2-yl]-n-(3-fluorophenyl)-3h-benzimidazole-5-carboxamide Chemical compound NC1=NC=C(C=2C=C(CCN3CC(CO)CCC3)C=CC=2)N=C1C(NC1=C2)=NC1=CC=C2C(=O)NC1=CC=CC(F)=C1 LIDKMOSULRVJAY-UHFFFAOYSA-N 0.000 description 1
- YFQMBHJIZOZXRE-UHFFFAOYSA-N 2-[3-amino-6-[3-[2-[4-(hydroxymethyl)piperidin-1-yl]ethyl]phenyl]pyrazin-2-yl]-3h-benzimidazole-5-carboxylic acid Chemical compound N1=C(C=2NC3=CC(=CC=C3N=2)C(O)=O)C(N)=NC=C1C(C=1)=CC=CC=1CCN1CCC(CO)CC1 YFQMBHJIZOZXRE-UHFFFAOYSA-N 0.000 description 1
- FUUKEFOENVRPOY-UHFFFAOYSA-N 2-[3-amino-6-[3-[2-[4-(hydroxymethyl)piperidin-1-yl]ethyl]phenyl]pyrazin-2-yl]-n-(3-fluorophenyl)-3h-benzimidazole-5-carboxamide Chemical compound NC1=NC=C(C=2C=C(CCN3CCC(CO)CC3)C=CC=2)N=C1C(NC1=C2)=NC1=CC=C2C(=O)NC1=CC=CC(F)=C1 FUUKEFOENVRPOY-UHFFFAOYSA-N 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- WIGDGIGALMYEBW-LLINQDLYSA-N 2-[[(2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-amino-4-methylpentanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]propanoyl]amino]-3-hydroxypropanoyl]amino]-4-methylpentanoyl]amino]acetic acid Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)NCC(O)=O WIGDGIGALMYEBW-LLINQDLYSA-N 0.000 description 1
- 125000000143 2-carboxyethyl group Chemical group [H]OC(=O)C([H])([H])C([H])([H])* 0.000 description 1
- FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 description 1
- UOKBFIOAEPCADP-UHFFFAOYSA-N 3-(hydroxymethyl)benzoic acid Chemical compound OCC1=CC=CC(C(O)=O)=C1 UOKBFIOAEPCADP-UHFFFAOYSA-N 0.000 description 1
- VOJIMZDHNFQRGR-UHFFFAOYSA-N 3-amino-6-[3-[2-[tert-butyl(dimethyl)silyl]oxyethyl]phenyl]pyrazine-2-carboxylic acid Chemical compound CC(C)(C)[Si](C)(C)OCCC1=CC=CC(C=2N=C(C(N)=NC=2)C(O)=O)=C1 VOJIMZDHNFQRGR-UHFFFAOYSA-N 0.000 description 1
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 1
- 235000019489 Almond oil Nutrition 0.000 description 1
- USFZMSVCRYTOJT-UHFFFAOYSA-N Ammonium acetate Chemical compound N.CC(O)=O USFZMSVCRYTOJT-UHFFFAOYSA-N 0.000 description 1
- 239000005695 Ammonium acetate Substances 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- 102000042871 Aurora family Human genes 0.000 description 1
- 108091082291 Aurora family Proteins 0.000 description 1
- 0 Bc(c(*)c1)cc2c1nc(-c1nc(-c3c(*)c(C)c(*)c(*)c3*)cnc1N)[n]2* Chemical compound Bc(c(*)c1)cc2c1nc(-c1nc(-c3c(*)c(C)c(*)c(*)c3*)cnc1N)[n]2* 0.000 description 1
- 229910014455 Ca-Cb Inorganic materials 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 108010024986 Cyclin-Dependent Kinase 2 Proteins 0.000 description 1
- 102100036239 Cyclin-dependent kinase 2 Human genes 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- BWLUMTFWVZZZND-UHFFFAOYSA-N Dibenzylamine Chemical compound C=1C=CC=CC=1CNCC1=CC=CC=C1 BWLUMTFWVZZZND-UHFFFAOYSA-N 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 239000004150 EU approved colour Substances 0.000 description 1
- 102100030011 Endoribonuclease Human genes 0.000 description 1
- 101710199605 Endoribonuclease Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 1
- 101000798306 Homo sapiens Aurora kinase B Proteins 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical class Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 description 1
- 229930064664 L-arginine Natural products 0.000 description 1
- 235000014852 L-arginine Nutrition 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 239000007993 MOPS buffer Substances 0.000 description 1
- 235000019759 Maize starch Nutrition 0.000 description 1
- HTLZVHNRZJPSMI-UHFFFAOYSA-N N-ethylpiperidine Chemical compound CCN1CCCCC1 HTLZVHNRZJPSMI-UHFFFAOYSA-N 0.000 description 1
- MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 description 1
- 238000012565 NMR experiment Methods 0.000 description 1
- 238000005481 NMR spectroscopy Methods 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- 101710163270 Nuclease Proteins 0.000 description 1
- 235000019502 Orange oil Nutrition 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 208000020584 Polyploidy Diseases 0.000 description 1
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical class [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 1
- 230000018199 S phase Effects 0.000 description 1
- 229910006074 SO2NH2 Inorganic materials 0.000 description 1
- 101710113029 Serine/threonine-protein kinase Proteins 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 239000004141 Sodium laurylsulphate Substances 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- QDVYNSDLTZYUIQ-UHFFFAOYSA-N [3-[2-[tert-butyl(dimethyl)silyl]oxyethyl]phenyl]boronic acid Chemical compound CC(C)(C)[Si](C)(C)OCCC1=CC=CC(B(O)O)=C1 QDVYNSDLTZYUIQ-UHFFFAOYSA-N 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000001464 adherent effect Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 150000008044 alkali metal hydroxides Chemical class 0.000 description 1
- 229910001860 alkaline earth metal hydroxide Inorganic materials 0.000 description 1
- 125000004414 alkyl thio group Chemical group 0.000 description 1
- 239000008168 almond oil Substances 0.000 description 1
- 125000003368 amide group Chemical group 0.000 description 1
- 235000019257 ammonium acetate Nutrition 0.000 description 1
- 229940043376 ammonium acetate Drugs 0.000 description 1
- VZTDIZULWFCMLS-UHFFFAOYSA-N ammonium formate Chemical compound [NH4+].[O-]C=O VZTDIZULWFCMLS-UHFFFAOYSA-N 0.000 description 1
- 230000003444 anaesthetic effect Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000001640 apoptogenic effect Effects 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 238000000149 argon plasma sintering Methods 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- 125000004429 atom Chemical group 0.000 description 1
- 229910052788 barium Inorganic materials 0.000 description 1
- DSAJWYNOEDNPEQ-UHFFFAOYSA-N barium atom Chemical compound [Ba] DSAJWYNOEDNPEQ-UHFFFAOYSA-N 0.000 description 1
- 150000001556 benzimidazoles Chemical class 0.000 description 1
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 description 1
- 125000004604 benzisothiazolyl group Chemical group S1N=C(C2=C1C=CC=C2)* 0.000 description 1
- 125000004603 benzisoxazolyl group Chemical group O1N=C(C2=C1C=CC=C2)* 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid group Chemical group C(C1=CC=CC=C1)(=O)O WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 description 1
- 125000004541 benzoxazolyl group Chemical group O1C(=NC2=C1C=CC=C2)* 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 239000004305 biphenyl Substances 0.000 description 1
- 235000010290 biphenyl Nutrition 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 125000001246 bromo group Chemical group Br* 0.000 description 1
- 239000006172 buffering agent Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 125000002837 carbocyclic group Chemical group 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 description 1
- 231100000504 carcinogenesis Toxicity 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 108091092328 cellular RNA Proteins 0.000 description 1
- 230000036755 cellular response Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 210000003793 centrosome Anatomy 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 125000001309 chloro group Chemical group Cl* 0.000 description 1
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
- 229960001231 choline Drugs 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 230000024321 chromosome segregation Effects 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 239000003240 coconut oil Substances 0.000 description 1
- 235000019864 coconut oil Nutrition 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- WZHCOOQXZCIUNC-UHFFFAOYSA-N cyclandelate Chemical class C1C(C)(C)CC(C)CC1OC(=O)C(O)C1=CC=CC=C1 WZHCOOQXZCIUNC-UHFFFAOYSA-N 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000000640 cyclooctyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- 230000021953 cytokinesis Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- YNHIGQDRGKUECZ-UHFFFAOYSA-N dichloropalladium;triphenylphosphanium Chemical compound Cl[Pd]Cl.C1=CC=CC=C1[PH+](C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1[PH+](C=1C=CC=CC=1)C1=CC=CC=C1 YNHIGQDRGKUECZ-UHFFFAOYSA-N 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 239000000890 drug combination Substances 0.000 description 1
- 238000009510 drug design Methods 0.000 description 1
- 239000008157 edible vegetable oil Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
- OAYLNYINCPYISS-UHFFFAOYSA-N ethyl acetate;hexane Chemical compound CCCCCC.CCOC(C)=O OAYLNYINCPYISS-UHFFFAOYSA-N 0.000 description 1
- DEFVIWRASFVYLL-UHFFFAOYSA-N ethylene glycol bis(2-aminoethyl)tetraacetic acid Chemical compound OC(=O)CN(CC(O)=O)CCOCCOCCN(CC(O)=O)CC(O)=O DEFVIWRASFVYLL-UHFFFAOYSA-N 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 239000003925 fat Substances 0.000 description 1
- 235000019197 fats Nutrition 0.000 description 1
- KTWOOEGAPBSYNW-UHFFFAOYSA-N ferrocene Chemical compound [Fe+2].C=1C=C[CH-]C=1.C=1C=C[CH-]C=1 KTWOOEGAPBSYNW-UHFFFAOYSA-N 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000003193 general anesthetic agent Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 235000001727 glucose Nutrition 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 102000044615 human AURKB Human genes 0.000 description 1
- 150000002430 hydrocarbons Chemical group 0.000 description 1
- 230000003301 hydrolyzing effect Effects 0.000 description 1
- NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 108010082683 kemptide Proteins 0.000 description 1
- 238000000021 kinase assay Methods 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 238000013332 literature search Methods 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- UEGPKNKPLBYCNK-UHFFFAOYSA-L magnesium acetate Chemical compound [Mg+2].CC([O-])=O.CC([O-])=O UEGPKNKPLBYCNK-UHFFFAOYSA-L 0.000 description 1
- 235000011285 magnesium acetate Nutrition 0.000 description 1
- 239000011654 magnesium acetate Substances 0.000 description 1
- 229940069446 magnesium acetate Drugs 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- VTHJTEIRLNZDEV-UHFFFAOYSA-L magnesium dihydroxide Chemical class [OH-].[OH-].[Mg+2] VTHJTEIRLNZDEV-UHFFFAOYSA-L 0.000 description 1
- 235000012254 magnesium hydroxide Nutrition 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 235000019341 magnesium sulphate Nutrition 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- GBMDVOWEEQVZKZ-UHFFFAOYSA-N methanol;hydrate Chemical compound O.OC GBMDVOWEEQVZKZ-UHFFFAOYSA-N 0.000 description 1
- FGZIEZWHOMPGDS-UHFFFAOYSA-N methyl 3-amino-6-[3-(hydroxymethyl)phenyl]pyrazine-2-carboxylate Chemical compound N1=C(N)C(C(=O)OC)=NC(C=2C=C(CO)C=CC=2)=C1 FGZIEZWHOMPGDS-UHFFFAOYSA-N 0.000 description 1
- CNXSIRHOIFRMOB-UHFFFAOYSA-N methyl 3-amino-6-bromopyrazine-2-carboxylate Chemical compound COC(=O)C1=NC(Br)=CN=C1N CNXSIRHOIFRMOB-UHFFFAOYSA-N 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 125000002950 monocyclic group Chemical group 0.000 description 1
- 230000000877 morphologic effect Effects 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001280 n-hexyl group Chemical group C(CCCCC)* 0.000 description 1
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 150000002825 nitriles Chemical class 0.000 description 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 1
- 239000002687 nonaqueous vehicle Substances 0.000 description 1
- 229940006093 opthalmologic coloring agent diagnostic Drugs 0.000 description 1
- 239000010502 orange oil Substances 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- 239000012044 organic layer Substances 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- 125000001715 oxadiazolyl group Chemical group 0.000 description 1
- 239000003182 parenteral nutrition solution Substances 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 150000002989 phenols Chemical class 0.000 description 1
- 239000002953 phosphate buffered saline Substances 0.000 description 1
- VUNPWIPIOOMCPT-UHFFFAOYSA-N piperidin-3-ylmethanol Chemical compound OCC1CCCNC1 VUNPWIPIOOMCPT-UHFFFAOYSA-N 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 210000001850 polyploid cell Anatomy 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000011118 potassium hydroxide Nutrition 0.000 description 1
- 229920001592 potato starch Polymers 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 238000012342 propidium iodide staining Methods 0.000 description 1
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 1
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
- 235000013772 propylene glycol Nutrition 0.000 description 1
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 125000004309 pyranyl group Chemical group O1C(C=CC=C1)* 0.000 description 1
- XFTQRUTUGRCSGO-UHFFFAOYSA-N pyrazin-2-amine Chemical group NC1=CN=CC=N1 XFTQRUTUGRCSGO-UHFFFAOYSA-N 0.000 description 1
- 125000004307 pyrazin-2-yl group Chemical group [H]C1=C([H])N=C(*)C([H])=N1 0.000 description 1
- 125000003373 pyrazinyl group Chemical group 0.000 description 1
- 125000002098 pyridazinyl group Chemical group 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 230000034394 regulation of mitosis Effects 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 230000003362 replicative effect Effects 0.000 description 1
- 125000006413 ring segment Chemical group 0.000 description 1
- 229930195734 saturated hydrocarbon Natural products 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 239000012321 sodium triacetoxyborohydride Substances 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 229940075582 sorbic acid Drugs 0.000 description 1
- 239000001593 sorbitan monooleate Substances 0.000 description 1
- 235000011069 sorbitan monooleate Nutrition 0.000 description 1
- 229940035049 sorbitan monooleate Drugs 0.000 description 1
- 238000012306 spectroscopic technique Methods 0.000 description 1
- 230000020347 spindle assembly Effects 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- WPLOVIFNBMNBPD-ATHMIXSHSA-N subtilin Chemical compound CC1SCC(NC2=O)C(=O)NC(CC(N)=O)C(=O)NC(C(=O)NC(CCCCN)C(=O)NC(C(C)CC)C(=O)NC(=C)C(=O)NC(CCCCN)C(O)=O)CSC(C)C2NC(=O)C(CC(C)C)NC(=O)C1NC(=O)C(CCC(N)=O)NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C1NC(=O)C(=C/C)/NC(=O)C(CCC(N)=O)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)CNC(=O)C(NC(=O)C(NC(=O)C2NC(=O)CNC(=O)C3CCCN3C(=O)C(NC(=O)C3NC(=O)C(CC(C)C)NC(=O)C(=C)NC(=O)C(CCC(O)=O)NC(=O)C(NC(=O)C(CCCCN)NC(=O)C(N)CC=4C5=CC=CC=C5NC=4)CSC3)C(C)SC2)C(C)C)C(C)SC1)CC1=CC=CC=C1 WPLOVIFNBMNBPD-ATHMIXSHSA-N 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- PXQLVRUNWNTZOS-UHFFFAOYSA-N sulfanyl Chemical compound [SH] PXQLVRUNWNTZOS-UHFFFAOYSA-N 0.000 description 1
- 239000001117 sulphuric acid Substances 0.000 description 1
- 235000011149 sulphuric acid Nutrition 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000002278 tabletting lubricant Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- BCNZYOJHNLTNEZ-UHFFFAOYSA-N tert-butyldimethylsilyl chloride Chemical compound CC(C)(C)[Si](C)(C)Cl BCNZYOJHNLTNEZ-UHFFFAOYSA-N 0.000 description 1
- 125000001302 tertiary amino group Chemical group 0.000 description 1
- 125000003396 thiol group Chemical class [H]S* 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 229940116362 tragacanth Drugs 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 125000004306 triazinyl group Chemical group 0.000 description 1
- 125000001425 triazolyl group Chemical group 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 125000001889 triflyl group Chemical group FC(F)(F)S(*)(=O)=O 0.000 description 1
- 230000001960 triggered effect Effects 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
Definitions
- This invention relates to substituted pyrazine compounds having Aurora A and Aurora B inhibitory activity, to the use of such compounds in medicine, in relation to the treatment of disorders which are responsive to inhibition of Aurora A and Aurora B such as cancer, and to pharmaceutical compositions containing such compounds.
- Aurora family of serine/threonine protein kinases are critical for proper regulation of mitosis in many organisms. They play a key role in diverse cell cycle events such as entry to mitosis, centrosome function, mitotic spindle formation, chromosome segregation and cytokinesis. Overexpression of Aurora kinases occur in a wide range of human tumours and have been implicated in human tumourigenesis. Mammals express three Aurora Kinase paralogues and at least two (Aurora A and Aurora B) are commonly overexpressed in human tumours. 1
- the present invention relates to a class of substituted pyrazine compounds useful as inhibitors of Aurora A and Aurora B, for example, for the treatment of cancer.
- a core amino pyrazine ring substituted on the heterocyclic ring with an optionally substituted benzimidazole is a principle characterising feature of the compounds with which the invention is concerned.
- R ⁇ is hydrogen, Ci-C 3 alkyl, or fluoro(Ci-C 3 )alkyl
- R 7 is C- 1 -C 3 alkyl, hydroxy-(C 1 -C 6 )alkyl, hydroxy-(Ci-C 6 )alkyl substituted on the alkyl portion by phenyl, C 1 -C 3 alkoxy-(Ci-C 3 )alkyl, halo(C 1 -C 4 )alkyl, or C 3 -C 6 cycloalkyl; or R 6 and R 7 taken together with the nitrogen atom to which they are attached form an optionally substituted monocyclic 5- or 6-membered heterocyclic ring;
- R 8 is selected from hydrogen, Ci-C 3 alkyl, fluoro(Ci-C 3 )alkyl, or a radical of formula -AIk-N(Rg)-Ri 0 ;
- Rg and Ri 0 are independently selected from hydrogen, Ci-C 3 alkyl, or fluoroCCrC ⁇ alkyl;
- Rg and Ri 0 taken together with the nitrogen atom to which they are attached form an optionally substituted monocyclic 5- or 6-membered heterocyclic ring;
- -AIk- is a divalent (Ci-C 4 )alkylene radical
- R is hydrogen or CrC 3 alkyl
- one of A and B is hydrogen and the other is a group -Z-Ar;
- Ar is aryl or heteroaryl, optionally substituted with one or more halogen atoms, Ci-C 3 alkyl radicals or trifluoromethyl radicals.
- the active compounds of formula (I) are inhibitors of Aurora Kinases, both A and B paralogues, and are useful for the treatment, prevention and suppression of diseases mediated by Aurora Kinases.
- the invention is concerned with the use of these compounds to selectively inhibit Aurora Kinases and, as such, in the treatment of cancer.
- (C a -Cb)alkyl wherein a and b are integers refers to a straight or branched chain alkyl radical having from a to b carbon atoms.
- a 1 and b is 6, for example, the term includes methyl, ethyl, n- propyl, isopropyl, n-butyl, isobutyl, sec-butyl, t-butyl, n-pentyl and n-hexyl.
- divalent (C a -Ct,)alkylene radical wherein a and b are integers refers to a saturated hydrocarbon chain having from a to b carbon atoms and two unsatisfied valences.
- cycloalkyl refers to a saturated carbocyclic radical having from 3-8 carbon atoms and includes, for example, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl and cyclooctyl.
- aryl refers to a mono-, bi- or tri-cyclic carbocyclic aromatic radical. Illustrative of such radicals are phenyl, biphenyl and napthyl.
- Carbocyclic refers to a cyclic radical whose ring atoms are all carbon, and includes monocyclic aryl, cycloalkyl and cycloalkenyl radicals.
- heteroaryl refers to a mono-, bi- or tri-cyclic aromatic radical containing one or more heteroatoms selected from S, N and O.
- Illustrative of such radicals are thienyl, benzthienyl, furyl, benzfuryl, pyrrolyl, imidazolyl, benzimidazolyl, thiazolyl, benzthiazolyl, isothiazolyl, benzisothiazolyl, pyrazolyl, oxazolyl, benzoxazolyl, isoxazolyl, benzisoxazolyl, isothiazolyl, triazolyl, benztriazolyl, thiadiazolyl, oxadiazolyl, pyridinyl, pyridazinyl, pyrimidinyl, pyrazinyl, triazinyl, indolyl and indazolyl.
- heterocyclyl or “heterocyclic” includes “heteroaryl” as defined above, and in particular means a mono-, bi- or tricyclic non-aromatic radical containing one or more heteroatoms selected from S, N and O, and to groups consisting of a monocyclic non-aromatic radical containing one or more such heteroatoms which is covalently linked to another such radical or to a monocyclic carbocyclic radical.
- radicals are pyrrolyl, furanyl, thienyl, piperidinyl, imidazolyl, oxazolyl, isoxazolyl, thiazolyl, thiadiazolyl, pyrazolyl, pyridinyl, pyrrolidinyl, pyrimidinyl, morpholinyl, piperazinyl, indolyl, morpholinyl, benzfuranyl, pyranyl, isoxazolyl, benzimidaz ⁇ lyl, methylenedioxyphenyl, ethylenedioxyphenyl, maleimido and succinimido groups.
- substituted as applied to any moiety herein means substituted with up to four compatible substituents, each of which independently may be, for example, (Ci-C 6 )alkyl, (Ci-C 6 )alkoxy, hydroxy, hydroxy(CrC 6 )alkyl, mercapto, mercapto(C r C 6 )alkyl, (Ci-C 6 )alkylthio, halo (including fluoro, bromo and chloro), trifluoromethyl, trifluoromethoxy, nitro, nitrile (-CN), oxo, phenyl, - COOH, -COOR A , -COR A , -SO 2 R A , -CONH 2 , -SO 2 NH 2 , -CONHR A , -SO 2 NHR A , -CONR A R B , -SO 2 NR A R B ,
- an “optional substituent” may be one of the foregoing substituent groups.
- substituents Ci-C 6 )alkyl, halo, trifluoromethyl, trifluoromethoxy, trifluoromethylsulfonyl, and phenyl are those most commonly regarded as lipophilic.
- substituents listed which contain alkyl groups may be lipophilic depending on the particular alkyl groups present.
- salt includes base addition, acid addition and quaternary salts.
- Compounds of the invention which are acidic can form salts, including pharmaceutically or veterinarily acceptable salts, with bases such as alkali metal hydroxides, e.g. sodium and potassium hydroxides; alkaline earth metal hydroxides e.g. calcium, barium and magnesium hydroxides; with organic bases e.g. N-methyl-D-glucamine, choline tris(hydroxymethyl)amino- methane, L-arginine, L-lysine, N-ethyl piperidine, dibenzylamine and the like.
- bases such as alkali metal hydroxides, e.g. sodium and potassium hydroxides; alkaline earth metal hydroxides e.g. calcium, barium and magnesium hydroxides; with organic bases e.g. N-methyl-D-glucamine, choline tris(hydroxymethyl)amino- methane, L-arginine, L-lysine, N-
- Those compounds (I) which are basic can form salts, including pharmaceutically or veterinarily acceptable salts with inorganic acids, e.g. with hydrohalic acids such as hydrochloric or hydrobromic acids, sulphuric acid, nitric acid or phosphoric acid and the like, and with organic acids e.g. with acetic, tartaric, succinic, fumaric, maleic, malic, salicylic, citric, methanesulphonic, p-toluenesulphonic, benzoic, benzenesunfonic, glutamic, lactic, and mandelic acids and the like.
- hydrohalic acids such as hydrochloric or hydrobromic acids, sulphuric acid, nitric acid or phosphoric acid and the like
- organic acids e.g. with acetic, tartaric, succinic, fumaric, maleic, malic, salicylic, citric, methanesulphonic, p-toluenes
- lipophilic as used herein in relation to a substituent means that it has a positive substituent hydrophobicity constant (D).
- D hydrophobicity constant
- 'solvate' is used herein to describe a molecular complex comprising the compound of the invention and a stoichiometric amount of one or more pharmaceutically acceptable solvent molecules, for example, ethanol.
- solvent molecules for example, ethanol.
- 'hydrate' is employed when said solvent is water.
- Compounds with which the invention is concerned which may exist in one or more stereoisomeric form, because of the presence of asymmetric atoms or rotational restrictions, can exist as a number of stereoisomers with R or S stereochemistry at each chiral centre or as atropisomeres with R or S stereochemistry at each chiral axis.
- the invention includes all such enantiomers and diastereoisomers and mixtures thereof.
- So-called 'pro-drugs' of the compounds of formula (I) are also within the scope of the invention.
- certain derivatives of compounds of formula (I) which may have little or no pharmacological activity themselves can, when administered into or onto the body, be converted into compounds of formula (I) having the desired activity, for example, by hydrolytic cleavage.
- Such derivatives are referred to as 'prodrugs'.
- Further information on the use of prodrugs may be found in Pro-drugs as Novel Delivery Systems. Vol. 14, ACS Symposium Series (T. Higuchi and W. Stella) and Bioreversible Carriers in Drug Design. Pergamon Press, 1987 (ed. E. B. Roche, American Pharmaceutical Association).
- Prodrugs in accordance with the invention can, for example, be produced by replacing appropriate functionalities present in the compounds of formula (I) with certain moieties known to those skilled in the art as 'pro-moieties' as described, for example, in Design of Prodrugs by H. Bundgaard (Elsevier, 1985).
- metabolites of compounds of formula (I), that is, compounds formed in vivo upon administration of the drug are also included within the scope of the invention.
- Some examples of metabolites include
- One subclass of compounds are those wherein Ri is selected from - AIk- N(R 6 )-R 7 , or -0-AIk-N(Re)-R 7 .
- AIk is a divalent (Ci-C 4 )alkylene radical
- R 6 is hydrogen or Ci-C 3 alkyl
- R 7 is Ci-C 3 alkyl, hydr ⁇ xy-(Ci- C ⁇ )alkyl, hydroxy-(Ci-Ce)alkyl substituted on the alkyl portion by phenyl, CrC 3 alkoxy-(Ci-C 3 )alkyl, halo Ci-C 4 alkyl, or C 3 -C 6 cycloalkyl; or alternatively R 6 and R 7 taken together with the nitrogen atom to which they are attached form an optionally substituted monocyclic 5- or 6-membered heterocyclic ring.
- AIk is methylene, -(CH 2 ) 2 - or -(CH 2 ) 3 -, R 6 is hydrogen, methyl or ethyl, and R 7 is methyl, ethyl, 2-hydroxyethyl, 2-methoxyethyl, 2,2,2- trifluoroethyl, cyclopentyl, -CH(JPr)-CH 2 -OH Or-CH(Ph)-CH 2 -OH.
- R 6 and R 7 taken together with the nitrogen atom to which they are attached form an optionally substituted monocyclic 6-membered heterocyclic ring, with morpholinyl, piperidinyl or piperazinyl optionally substituted by hydroxymethyl, fluoro, hydroxy, methyl, 2-hydroxyethyl, or trifluoromethyl presently preferred.
- AIk is methylene or -(CH 2 ) 2 -
- R 6 is hydrogen, methyl or ethyl
- R 7 is 2-hydroxyethyl, 2-methoxyethyl, - CH(iPr)-CH 2 -OH Or-CH(Ph)-CH 2 -OH
- AIk is methylene or -(CH 2 ) 2 -, and R 6 and R 7 taken together with the nitrogen atom to which they are attached form 1-fluoro-piperidin-3-yl, 1-hydroxy-piperidin-3-yl, 1-hydroxymethyl-piperidin-3- yl, 1-hydroxymethyl-piperidin-4-yl, 1 -methyI-piperidin-3-yl, 1-(2-hydroxyethyl)- piperidin-3-yl, or 1-trifluoromethyl-piperidin-3-yl.
- R 8 is selected from hydrogen, Ci-C 3 alkyl or a radical of formula -AIk-N(Rg)-Ri 0 , wherein AIk is a divalent (Ci-C 4 )alkylene radical and Rg and Ri 0 are independently selected from hydrogen or C1-C3 alkyl; or R 9 and R10 taken together with the nitrogen atom to which they are attached form an optionally substituted monocyclic 5- or 6-membered heterocyclic ring.
- R 8 is a radical of formula -AIk- N(Rg)-Ri O , wherein AIk is methylene or -(CH 2 ) 2 -, and Rg and R 10 taken together with the nitrogen atom to which they are attached form optionally substituted piperidinyl or pyrrolidinyl.
- Particulary preferred compounds are those wherein AIk is methylene or -(CH 2 ) 2 -, and R 9 and R10 taken together with the nitrogen atom to which they are attached form piperidin-1-yl, 1- methyl-piperidin-2-yl, 1-hydroxy-piperidin-4-yl, or 1 -ethyl-pyrrolidin-2-yl.
- Ri is selected from hydroxy(Ci-C 3 )alkyl. It is presently preferred that Ri is hydroxymethyl or 2- hydroxyethyl.
- Ri is selected from carboxy(Ci-C 3 )alkyl. It is presently preferred that Ri is carboxymethyl or 2- carboxyethyl.
- R 2 , R3, R 4 and R 5 are independently selected as for R 1 .
- Ri, R 2 , R 3 , R 4 and R 5 generally at least three are hydrogen. Preferred cases are wherein Ri, R 2 and R 5 are hydrogen; R 1 , R 2 , R 4 and R 5 are hydrogen; or R 1 , R 2 , R 3 and R 5 are hydrogen. Particularly preferred cases are wherein R 1 , R 2 , R 4 and R 5 are hydrogen; or R 1 , R 2 , R 3 and R 5 are hydrogen.
- R R is hydrogen or C- 1 -C 3 alkyl. It is presently preferred that R is hydrogen or methyl.
- Particularly preferred structures are those wherein Ar is phenyl, 2-fluorophenyl, 3-fluorophenyl, 2,3- difluorophenyl, 2,4-difluorophenyl, 3,4-difluorophenyl, 3,5-difluorophenyl, 3- chlorophenyl, 3-methylphenyl, or 3-trifluoromethylphenyl.
- R 3 is hydrogen or C 1 -C 3 alkyl
- R 4 is Ci-C 3 alkyl, hydroxy-(C 1 -C 6 )alkyl, hydroxy-(C 1 -C 6 )alkyl substituted on the alkyl portion by phenyl, C1-C 3 alkoxy-(Ci-C 3 )alkyl, halo CrC 4 alkyl, or C 3 -C 6 cycloalkyl;
- R 3 and R 4 taken together with the nitrogen atom to which they are attached form an optionally substituted monocyclic 6-membered heterocyclic ring;
- R 5 and Re taken together with the nitrogen atom to which they are attached form an optionally substituted monocyclic 5- or 6-membered heterocyclic ring;
- Ar 1 is -1 ,3-phenylene or -1 ,4-phenylene
- R is hydrogen or methyl
- one of A and B is hydrogen and the other is a group -Z-Ar 2 ;
- Ar 2 is halo- or Ci-C 3 alkyl- substituted phenyl.
- a method of treatment of a disorder mediated by Aurora Kinases comprising administration to a subject in need of such treatment an effective dose of the compound of formula (I), or a pharmaceutically acceptable salt or prodrug thereof.
- the present invention is particularly directed to a hyperproliferative disease such as cancer, wherein the cancer is colorectal, breast, lung, prostate, bladder, renal or pancreatic cancer, or leukaemia or lymphoma.
- the present invention may be employed in respect of a human or animal subject, more preferably a mammal, more preferably a human subject.
- treatment includes prophylactic treatment.
- the compound of formula (I) may be used in combination with one or more additional drugs useful in the treatment of the disorders mentioned above, the components being in the same formulation or in separate formulations for administration simultaneously or sequentially.
- a suitable dose for orally administrable formulations will usually be in the range of 0.1 to 3000 mg, once, twice or three times per day, or the equivalent daily amount administered by infusion or other routes.
- optimum dose levels and frequency of dosing will be determined by clinical trials as is conventional in the art.
- the compounds with which the invention is concerned may be prepared for administration by any route consistent with their pharmacokinetic properties.
- the orally administrable compositions may be in the form of tablets, capsules, powders, granules, lozenges, liquid or gel preparations, such as oral, topical, or sterile parenteral solutions or suspensions.
- Tablets and capsules for oral administration may be in unit dose presentation form, and may contain conventional excipients such as binding agents, for example syrup, acacia, gelatin, sorbitol, tragacanth, or polyvinyl-pyrrolidone; fillers for example lactose, sugar, maize-starch, calcium phosphate, sorbitol or glycine; tabletting lubricant, for example magnesium stearate, talc, polyethylene glycol or silica; disintegrants for example potato starch, or acceptable wetting agents such as sodium lauryl sulphate.
- the tablets may be coated according to methods well known in normal pharmaceutical practice.
- Oral liquid preparations may be in the form of, for example, aqueous or oily suspensions, solutions, emulsions, syrups or elixirs, or may be presented as a dry product for reconstitution with water or other suitable vehicle before use.
- Such liquid preparations may contain conventional additives such as suspending agents, for example sorbitol, syrup, methyl cellulose, glucose syrup, gelatin hydrogenated edible fats; emulsifying agents, for example lecithin, sorbitan monooleate, or acacia; non-aqueous vehicles (which may include edible oils), for example almond oil, fractionated coconut oil, oily esters such as glycerine, propylene glycol, or ethyl alcohol; preservatives, for example methyl or propyl p-hydroxybenzoate or sorbic acid, and if desired conventional flavouring or colouring agents.
- suspending agents for example sorbitol, syrup, methyl cellulose, glucose syrup, gelatin hydrogenated edible fats
- emulsifying agents for example lecithin, sorbitan monooleate, or acacia
- non-aqueous vehicles which may include edible oils
- almond oil fractionated coconut oil
- oily esters such as glycerine, propylene
- the drug may be made up into a cream, lotion or ointment.
- Cream or ointment formulations which may be used for the drug are conventional formulations well known in the art, for example as described in standard textbooks of pharmaceutics such as the British Pharmacopoeia.
- the active ingredient may also be administered parenterally in a sterile medium.
- the drug can either be suspended or dissolved in the vehicle.
- adjuvants such as a local anaesthetic, preservative and buffering agents can be dissolved in the vehicle.
- the cooled reaction mixture was diluted with EtOAc (20ml) and washed with 2N (aq) HCI (20ml). The separated organic layer was washed with brine, dried (MgSO ⁇ and condensed.
- the crude orange solid was suspended in DME (30ml), MnO 2 (1.02g, 11.7 mmol) was added and heated at 95°C for 6 hr. The reaction mixture was filtered through a plug of celite and condensed.
- Examples 7 to 59 listed in the following table were prepared by methods analogous to Examples 1 to 6 above. All 59 compounds were tested for activity in kinase assays described below in the Assay section.
- characterization and/or purification were performed using standard spectroscopic and chromatographic techniques, including liquid chromatography-mass spectroscopy (LC-MS) and high performance liquid chromatography (HPLC), using the conditions described in methods A, B and C.
- NMR experiments were conducted on a Bruker DPX400 ultra shield NMR spectrometer in the specified solvent. Reactions carried out under microwave irradiation were conducted in a Smith Synthesizer.
- Ionization was positive or negative ion electrospray Molecular weight scan range was 120-1000
- Ionization was positive or negative ion electrospray
- Assays for the Aurora A Kinase activity were carried out by monitoring the phosphorylation of a synthetic peptide, Kemptide (LRRASLG).
- the assay mixture containing the inhibitor, Aurora A enzyme, and peptide was mixed together in a microtiter plate in a final volume of 50 ⁇ l and incubated for 30min at 3O 0 C.
- the assay mixture contained 0.01 mM unlabeled ATP, 0.01 ⁇ Ci/ ⁇ l 33 P- ⁇ -ATP, 0.2mM peptide, 0.1 mg/ml BSA, 7.5mM magnesium acetate, 0.04M MOPS, pH 7, 1mM EDTA.
- the reaction was stopped by adding 50 ⁇ l of 5OmM phosphoric acid.
- Assays for the human Aurora B Kinase activity were carried out by monitoring the phosphorylation of a synthetic peptide, Paktide (RRRLSFEPG).
- the assay mixture containing the inhibitor, human Aurora B enzyme, and peptide was mixed together in a microtiter plate in a final volume of 50 ⁇ l and incubated for 30min at 30°C.
- the assay mixture contained 0.01 mM unlabeled ATP, 0.01 ⁇ Ci/ ⁇ l 33 P- ⁇ -ATP, 140 ⁇ M peptide, 0.05% Brij 35, 5OmM magnesium chloride, 25OmM Hepes, pH 7.5, 5mM EGTA.
- the reaction was stopped by adding 50 ⁇ l of 5OmM phosphoric acid.
- Example 5 gave an IC 50 versus Aurora A kinase of O.O ⁇ O ⁇ M and an IC 50 versus Aurora B kinase of O.OO ⁇ M.
- Fluorescence-activated cell-sorting is a trademarked employed by Becton-Dickinson to describe their method of flow cytometry (FCM).
- FCM Fluorescence-activated cell-sorting
- FCM flow cytometry
- a flow cytometer operates by causing a fluid stream to pass single file through a beam of light usually generated by a laser.
- the photons of light emitted by the cells, following their interaction with the laser beam, are separated into constituent wavelengths by a series of filters and mirrors. This separated light falls upon individual detectors that generate electrical impulses or analogue signals proportional to the amount of light striking the detectors.
- Each analogue signal is converted to a digital signal which is accumulated in a frequency distribution or histogram (see figure below).
- FCM is commonly used to quantify the volume and morphological complexity of cells, enzymatic activity and the quantification and measurement of DNA degradation.
- the assay has been designed for DNA cell cycle analysis using Propidium Iodide staining of the DNA.
- HCT-116 cells are grown and maintained by methods that will be familiar to those skilled in the art. For flow cytometry cells are counted and split into a 24-well plate at 30000 cells/well. The next day putative Aurora inhibitors are added at a range of appropriate concentrations (usually tripling dilution series are used). 48 hours later, floating cells are removed, then combined with the corresponding adherent cells that released by treatment with trypsin using methods familiar to those skilled in the art.
- the combined cell population is pelleted by 5 minutes centrifugation at 200 x g, washed with phosphate buffered saline, then resuspended in a solution containing (50 ug/ml propidium iodide and 0.5 mg/ml RNAase A). 1 hour of incubation at 37 C is sufficient for the digestion of cellular RNAs enabling the amount of propidium iodide associated with cells to be proportional to their DNA content.
- Samples are then read on a BD FACSArray with the amount of propidium iodine staining being measured for each cell; this yields a fluorescence histogram that plots the number of cells with a particular fluorescence against propidium iodide fluorescence.
- Untreated cells are bimodally distributed on such a fluorescence histogram with a large peak representing cells with a 2n DNA content (G 1 cells) and a smaller peak composed of cells with approximately double the fluorescence of the first peak representing cells with a 4n DNA content (cells in G2 and mitosis); cells with an intermediate fluorescence represent cells in S phase.
- Treatment with a pure Aurora A inhibitor is predicted to lead to a sharp increase in the number of cells with a 4n DNA content (though this was not observed for our compounds).
- Treatment of cells with an Aurora B inhibitor leads to failed cell division, followed by an attempt to re-replicate the genome which leads to the appearance of an 8n peak.
- the co- inhibition of kinases required for replication will prevent the appearance of the 8n peak and the co-inhibition of kinases required for survival under the culture conditions of the HCT116 cells will result in the appearance of apoptotic cells, which due to the activation of nucleases, will have a DNA content of ⁇ 2n.
- the range of doses that leads to the appearance of a peak of 8n cells, without the induction of a major sub 2n peak can be used as an indication of the dose range at which an inhibitor imposes an Aurora B blockade without confounding effects on other targets.
- Example 27 shows 8n down to 0.25 ⁇ M concentrations.
- Example 5 shows 8n down to 0.74 ⁇ M.
- Example 40 also shows 8n down to 0.74 ⁇ M.
Abstract
Compounds of formula (I) and their use in therapy, particularly for the treatment of a disorder responsive to inhibition of Aurora kinase A and/or B. Formula (I) wherein R1, R2, R3, R4 and R5 are independently selected from hydrogen, hydroxy, C1- C3 alkyl, fluoro(C1-C3)alkyl, hydroxy(C1-C3)alkyl, C1-C3 alkoxy, fluoro(C1- C3)alkoxy, hydroxyC1-C3alkoxy, -N(R6J-R7, - AIk-N(R6)-R7, -0-AIk-N(R6)-R7, - C(=O)OH, carboxy(C1-C3)alkyl, or -C(=O)-NH-R8; R6, R7,R8 and -AIk- are as defined herein; R is hydrogen or C1C3 alkyl; one of A and B is hydrogen and the other is a group -Z-Ar; -Z- is -C(=O)-NH-, -NH-C(=O)-, -C(=O)-N(-CH3)-, or -N(-CH3)-C(=O)-; and Ar is aryl or heteroaryl, optionally substituted with one or more halogen atoms, C1-C3 alkyl radicals or trifluoromethyl radicals; or a pharmaceutically acceptable salt, hydrate or solvate thereof.
Description
Pyrazine Derivatives And Their Use In Therapy
This invention relates to substituted pyrazine compounds having Aurora A and Aurora B inhibitory activity, to the use of such compounds in medicine, in relation to the treatment of disorders which are responsive to inhibition of Aurora A and Aurora B such as cancer, and to pharmaceutical compositions containing such compounds.
Background to the invention
Aurora Kinases
The Aurora family of serine/threonine protein kinases are critical for proper regulation of mitosis in many organisms. They play a key role in diverse cell cycle events such as entry to mitosis, centrosome function, mitotic spindle formation, chromosome segregation and cytokinesis. Overexpression of Aurora kinases occur in a wide range of human tumours and have been implicated in human tumourigenesis. Mammals express three Aurora Kinase paralogues and at least two (Aurora A and Aurora B) are commonly overexpressed in human tumours.1
Inhibition of the Aurora Kinase activity in tumour cell lines typically leads to the accumulation of polyploid cells, apoptosis and block of proliferation.2'3 In-vivo "small molecule" inhibitors of Aurora kinases have recently demonstrated remarkable efficacy in animal tumour models. VX-680, a potent specific inhibitor or Aurora A and Aurora B kinases, has been shown to suppress tumour growth in-vivo and this agent has progressed into clinical trials.4 Agents that inhibit Aurora kinases may therefore be useful for the therapy of cancer.
1 EMBO J. 1998, 17, 3052
2 EMBO J. 2002, 21 , 483
3 J. Cell Biol. 2003, 161 (2), 267-280
4 Nat. Med. 2004, 10(3), 262-327
Brief description of the invention
The present invention relates to a class of substituted pyrazine compounds useful as inhibitors of Aurora A and Aurora B, for example, for the treatment of cancer. A core amino pyrazine ring substituted on the heterocyclic ring with an optionally substituted benzimidazole is a principle characterising feature of the compounds with which the invention is concerned.
Detailed description of the invention
According to the present invention, there is provided a compound of formula (I) or a pharmaceutically acceptable salt, hydrate or solvate thereof
(I)
wherein
Ri, R2, R3, R4 and R5 are independently selected from hydrogen, hydroxy, Cr C3 alkyl, fluoro(Ci-C3)alkyl, hydroxy(Ci-C3)alkyl, C1-C3 alkoxy, fluoro(Ci- C3)alkoxy, hydroxy(C1-C3)alkoxy, -N(Re)-Rr1 - AIk-N(Re)-R7, -O-Alk-N(R6)-R7, - C(=O)OH, carboxytd-C^alkyl, or -C(=O)-NH~R8;
Rβ is hydrogen, Ci-C3 alkyl, or fluoro(Ci-C3)alkyl, and
R7 is C-1-C3 alkyl, hydroxy-(C1-C6)alkyl, hydroxy-(Ci-C6)alkyl substituted on the alkyl portion by phenyl, C1-C3 alkoxy-(Ci-C3)alkyl, halo(C1-C4)alkyl, or C3-C6 cycloalkyl;
or R6 and R7 taken together with the nitrogen atom to which they are attached form an optionally substituted monocyclic 5- or 6-membered heterocyclic ring;
R8 is selected from hydrogen, Ci-C3 alkyl, fluoro(Ci-C3)alkyl, or a radical of formula -AIk-N(Rg)-Ri0;
Rg and Ri0 are independently selected from hydrogen, Ci-C3 alkyl, or fluoroCCrC^alkyl;
or Rg and Ri0 taken together with the nitrogen atom to which they are attached form an optionally substituted monocyclic 5- or 6-membered heterocyclic ring;
-AIk- is a divalent (Ci-C4)alkylene radical;
R is hydrogen or CrC3 alkyl;
one of A and B is hydrogen and the other is a group -Z-Ar;
-Z- is -C(=O)-NH- , -NH-C(=O)-, -C(=O)-N(-CH3)-, or -N(-CH3)-C(=O)- ; and
Ar is aryl or heteroaryl, optionally substituted with one or more halogen atoms, Ci-C3 alkyl radicals or trifluoromethyl radicals.
The active compounds of formula (I) are inhibitors of Aurora Kinases, both A and B paralogues, and are useful for the treatment, prevention and suppression of diseases mediated by Aurora Kinases. The invention is concerned with the use of these compounds to selectively inhibit Aurora Kinases and, as such, in the treatment of cancer.
As used herein the term "carboxy" refers to a group of formula -COOH.
03687
As used herein, the term "(Ca-Cb)alkyl" wherein a and b are integers refers to a straight or branched chain alkyl radical having from a to b carbon atoms. Thus when a is 1 and b is 6, for example, the term includes methyl, ethyl, n- propyl, isopropyl, n-butyl, isobutyl, sec-butyl, t-butyl, n-pentyl and n-hexyl.
As used herein the term "divalent (Ca-Ct,)alkylene radical" wherein a and b are integers refers to a saturated hydrocarbon chain having from a to b carbon atoms and two unsatisfied valences..
As used herein the term "cycloalkyl" refers to a saturated carbocyclic radical having from 3-8 carbon atoms and includes, for example, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl and cyclooctyl.
As used herein the term "aryl" refers to a mono-, bi- or tri-cyclic carbocyclic aromatic radical. Illustrative of such radicals are phenyl, biphenyl and napthyl.
As used herein the term "carbocyclic" refers to a cyclic radical whose ring atoms are all carbon, and includes monocyclic aryl, cycloalkyl and cycloalkenyl radicals.
As used herein the term "heteroaryl" refers to a mono-, bi- or tri-cyclic aromatic radical containing one or more heteroatoms selected from S, N and O. Illustrative of such radicals are thienyl, benzthienyl, furyl, benzfuryl, pyrrolyl, imidazolyl, benzimidazolyl, thiazolyl, benzthiazolyl, isothiazolyl, benzisothiazolyl, pyrazolyl, oxazolyl, benzoxazolyl, isoxazolyl, benzisoxazolyl, isothiazolyl, triazolyl, benztriazolyl, thiadiazolyl, oxadiazolyl, pyridinyl, pyridazinyl, pyrimidinyl, pyrazinyl, triazinyl, indolyl and indazolyl.
As used herein the unqualified term "heterocyclyl" or "heterocyclic" includes "heteroaryl" as defined above, and in particular means a mono-, bi- or tricyclic non-aromatic radical containing one or more heteroatoms selected from S, N and O, and to groups consisting of a monocyclic non-aromatic radical containing one or more such heteroatoms which is covalently linked to another such radical or to a monocyclic carbocyclic radical. Illustrative of such
radicals are pyrrolyl, furanyl, thienyl, piperidinyl, imidazolyl, oxazolyl, isoxazolyl, thiazolyl, thiadiazolyl, pyrazolyl, pyridinyl, pyrrolidinyl, pyrimidinyl, morpholinyl, piperazinyl, indolyl, morpholinyl, benzfuranyl, pyranyl, isoxazolyl, benzimidazσlyl, methylenedioxyphenyl, ethylenedioxyphenyl, maleimido and succinimido groups.
Unless otherwise specified in the context in which it occurs, the term "substituted" as applied to any moiety herein means substituted with up to four compatible substituents, each of which independently may be, for example, (Ci-C6)alkyl, (Ci-C6)alkoxy, hydroxy, hydroxy(CrC6)alkyl, mercapto, mercapto(CrC6)alkyl, (Ci-C6)alkylthio, halo (including fluoro, bromo and chloro), trifluoromethyl, trifluoromethoxy, nitro, nitrile (-CN), oxo, phenyl, - COOH, -COORA, -CORA, -SO2RA, -CONH2, -SO2NH2, -CONHRA, -SO2NHRA, -CONRARB, -SO2NRARB, -NH2, -NHRA, -NRARB, -OCONH2, -OCONHRA , -OCONRARB, -NHCORA, -NHCOORA, -NRBCOORA, -NHSO2ORA, -NR6SO2OH, -NRBSO2ORA,-NHCONH2, -NRACONH2, -NHCONHR6 -NRACONHRB, -NHCONRARB or -NRACONRARB wherein RA and RB are independently a (CrC6)alkyl group. An "optional substituent" may be one of the foregoing substituent groups. Of the above substituents, (Ci-C6)alkyl, halo, trifluoromethyl, trifluoromethoxy, trifluoromethylsulfonyl, and phenyl are those most commonly regarded as lipophilic. Other substituents listed which contain alkyl groups may be lipophilic depending on the particular alkyl groups present.
As used herein the term "salt" includes base addition, acid addition and quaternary salts. Compounds of the invention which are acidic can form salts, including pharmaceutically or veterinarily acceptable salts, with bases such as alkali metal hydroxides, e.g. sodium and potassium hydroxides; alkaline earth metal hydroxides e.g. calcium, barium and magnesium hydroxides; with organic bases e.g. N-methyl-D-glucamine, choline tris(hydroxymethyl)amino- methane, L-arginine, L-lysine, N-ethyl piperidine, dibenzylamine and the like. Those compounds (I) which are basic can form salts, including pharmaceutically or veterinarily acceptable salts with inorganic acids, e.g. with hydrohalic acids such as hydrochloric or hydrobromic acids, sulphuric acid,
nitric acid or phosphoric acid and the like, and with organic acids e.g. with acetic, tartaric, succinic, fumaric, maleic, malic, salicylic, citric, methanesulphonic, p-toluenesulphonic, benzoic, benzenesunfonic, glutamic, lactic, and mandelic acids and the like.
The term "lipophilic" as used herein in relation to a substituent means that it has a positive substituent hydrophobicity constant (D). (A positive value for D indicates that the substituent is more lipophilic than hydrogen, whereas a negative value indicates it is less lipophilic, i.e. more hydrophilic, than hydrogen).
For a review on suitable salts, see Handbook of Pharmaceutical Salts: Properties. Selection, and Use by Stahl and Wermuth (Wiiey-VCH, Weinheim, Germany, 2002).
The term 'solvate' is used herein to describe a molecular complex comprising the compound of the invention and a stoichiometric amount of one or more pharmaceutically acceptable solvent molecules, for example, ethanol. The term 'hydrate' is employed when said solvent is water.
Compounds with which the invention is concerned which may exist in one or more stereoisomeric form, because of the presence of asymmetric atoms or rotational restrictions, can exist as a number of stereoisomers with R or S stereochemistry at each chiral centre or as atropisomeres with R or S stereochemistry at each chiral axis. The invention includes all such enantiomers and diastereoisomers and mixtures thereof.
So-called 'pro-drugs' of the compounds of formula (I) are also within the scope of the invention. Thus certain derivatives of compounds of formula (I) which may have little or no pharmacological activity themselves can, when administered into or onto the body, be converted into compounds of formula (I) having the desired activity, for example, by hydrolytic cleavage. Such derivatives are referred to as 'prodrugs'. Further information on the use of prodrugs may be found in Pro-drugs as Novel Delivery Systems. Vol. 14, ACS
Symposium Series (T. Higuchi and W. Stella) and Bioreversible Carriers in Drug Design. Pergamon Press, 1987 (ed. E. B. Roche, American Pharmaceutical Association).
Prodrugs in accordance with the invention can, for example, be produced by replacing appropriate functionalities present in the compounds of formula (I) with certain moieties known to those skilled in the art as 'pro-moieties' as described, for example, in Design of Prodrugs by H. Bundgaard (Elsevier, 1985).
Also included within the scope of the invention are metabolites of compounds of formula (I), that is, compounds formed in vivo upon administration of the drug. Some examples of metabolites include
(i) where the compound of formula (I) contains a methyl group, an hydroxymethyl derivative thereof (-CH3 -> -CH2OH):
(ii) where the compound of formula (I) contains an alkoxy group, an hydroxy derivative thereof (-OR -> -OH);
where the compound of formula (I) contains a tertiary amino group, a secondary amino derivative thereof (-NR1R2 -> -NHR1 or -NHR2);
(iv) where the compound of formula (I) contains a secondary amino group, a primary derivative thereof (-NHR1 -> -NH2);
(v) where the compound of formula (I) contains a phenyl moiety, a phenol derivative thereof (-Ph -> -PhOH); and
(vi) where the compound of formula (I) contains an amide group, a carboxylic acid derivative thereof (-CONH2 -> COOH).
The radical R1
Ri is selected from hydrogen, hydroxy, Ci-C3 alkyl, fluoro(Ci-C3)alkyl, hydroxy(C1-C3)alkyl, Ci-C3 alkoxy, fluoro(Ci-C3)alkoxy, hydroxy(Ci-C3)alkoxy, -N(Re)-R71 - AIk-N(Re)-R7, -0-AIk-N(Re)-R7, -C(=O)OH, carboxy(Ci-C3)alkyl, or -C(=O)-NH-R8.
One subclass of compounds are those wherein Ri is selected from - AIk- N(R6)-R7, or -0-AIk-N(Re)-R7. In such cases AIk is a divalent (Ci-C4)alkylene radical; R6 is hydrogen or Ci-C3 alkyl, and R7 is Ci-C3 alkyl, hydrσxy-(Ci- Cβ)alkyl, hydroxy-(Ci-Ce)alkyl substituted on the alkyl portion by phenyl, CrC3 alkoxy-(Ci-C3)alkyl, halo Ci-C4 alkyl, or C3-C6 cycloalkyl; or alternatively R6 and R7 taken together with the nitrogen atom to which they are attached form an optionally substituted monocyclic 5- or 6-membered heterocyclic ring. It is currently preferred that AIk is methylene, -(CH2)2- or -(CH2)3-, R6 is hydrogen, methyl or ethyl, and R7 is methyl, ethyl, 2-hydroxyethyl, 2-methoxyethyl, 2,2,2- trifluoroethyl, cyclopentyl, -CH(JPr)-CH2-OH Or-CH(Ph)-CH2-OH. Alternatively, R6 and R7 taken together with the nitrogen atom to which they are attached form an optionally substituted monocyclic 6-membered heterocyclic ring, with morpholinyl, piperidinyl or piperazinyl optionally substituted by hydroxymethyl, fluoro, hydroxy, methyl, 2-hydroxyethyl, or trifluoromethyl presently preferred. In a particulary preferred subclass of compounds AIk is methylene or -(CH2)2-, R6 is hydrogen, methyl or ethyl, and R7 is 2-hydroxyethyl, 2-methoxyethyl, - CH(iPr)-CH2-OH Or-CH(Ph)-CH2-OH; or AIk is methylene or -(CH2)2-, and R6 and R7 taken together with the nitrogen atom to which they are attached form 1-fluoro-piperidin-3-yl, 1-hydroxy-piperidin-3-yl, 1-hydroxymethyl-piperidin-3- yl, 1-hydroxymethyl-piperidin-4-yl, 1 -methyI-piperidin-3-yl, 1-(2-hydroxyethyl)- piperidin-3-yl, or 1-trifluoromethyl-piperidin-3-yl.
Another subclass of compounds are those wherein Ri is selected from - C(=O)-NH-R8. In such cases R8 is selected from hydrogen, Ci-C3 alkyl or a radical of formula -AIk-N(Rg)-Ri0, wherein AIk is a divalent (Ci-C4)alkylene radical and Rg and Ri0 are independently selected from hydrogen or C1-C3 alkyl; or R9 and R10 taken together with the nitrogen atom to which they are attached form an optionally substituted monocyclic 5- or 6-membered heterocyclic ring. It is presently preferred that R8 is a radical of formula -AIk-
N(Rg)-RiO, wherein AIk is methylene or -(CH2)2-, and Rg and R10 taken together with the nitrogen atom to which they are attached form optionally substituted piperidinyl or pyrrolidinyl. Particulary preferred compounds are those wherein AIk is methylene or -(CH2)2-, and R9 and R10 taken together with the nitrogen atom to which they are attached form piperidin-1-yl, 1- methyl-piperidin-2-yl, 1-hydroxy-piperidin-4-yl, or 1 -ethyl-pyrrolidin-2-yl.
In another subclass of compounds Ri is selected from hydrogen.
In yet another subclass of compounds Ri is selected from hydroxy.
Another subclass of compounds are those wherein Ri is selected from hydroxy(Ci-C3)alkyl. It is presently preferred that Ri is hydroxymethyl or 2- hydroxyethyl.
In a further subclass of compounds Ri is selected from -C(=O)OH.
Another subclass of compounds are those wherein Ri is selected from carboxy(Ci-C3)alkyl. It is presently preferred that Ri is carboxymethyl or 2- carboxyethyl.
The radicals R2, R3, R4 and R5
R2, R3, R4 and R5 are independently selected as for R1.
Of the radicals Ri, R2, R3, R4 and R5, generally at least three are hydrogen. Preferred cases are wherein Ri, R2 and R5 are hydrogen; R1, R2, R4 and R5 are hydrogen; or R1, R2, R3 and R5 are hydrogen. Particularly preferred cases are wherein R1, R2, R4 and R5 are hydrogen; or R1, R2, R3 and R5 are hydrogen.
Group R
R is hydrogen or C-1-C3 alkyl. It is presently preferred that R is hydrogen or methyl.
Groups A and B
One of A and B is hydrogen and the other is a group -Z-Ar, wherein -Z- is - C(=O)-NH- , -NH-C(=O)-, -C(=O)-N(-CH3)-, or -N(-CH3)-C(=O)- and Ar is aryl or heteroaryl, optionally substituted with one or more halogen atoms, C1-C3 alkyl radicals or trifluoromethyl radicals. It is presently preferred that aryl is phenyl and heteroaryl is pyridyl or N-oxido-pyridyl. Particularly preferred structures are those wherein Ar is phenyl, 2-fluorophenyl, 3-fluorophenyl, 2,3- difluorophenyl, 2,4-difluorophenyl, 3,4-difluorophenyl, 3,5-difluorophenyl, 3- chlorophenyl, 3-methylphenyl, or 3-trifluoromethylphenyl.
A preferred subclass of the compounds with which the invention is concerned has formula (II):
(II)
wherein
R1 is hydrogen, hydroxy, hydroxy(CrC3)alkyl, -C(=O)OH, carboxy(C-i- C3)alkyl, hyd TOXy(C1 -C3)alkoxy, a radical of formula -(CH2)n-N(R3)-R4 wherein n is 1 or 2, a radical of formula -O-(CH2)n-N(R3)-R4 wherein n is 1 or 2, or a radical of formula -C(=O)-NH-(CH2)p-N(R5)-R6 wherein p is 1 , 2 or 3;
R3 is hydrogen or C1-C3 alkyl, and
R4 is Ci-C3 alkyl, hydroxy-(C1-C6)alkyl, hydroxy-(C1-C6)alkyl substituted on the alkyl portion by phenyl, C1-C3 alkoxy-(Ci-C3)alkyl, halo CrC4 alkyl, or C3-C6 cycloalkyl;
or R3 and R4 taken together with the nitrogen atom to which they are attached form an optionally substituted monocyclic 6-membered heterocyclic ring;
R5 and Re taken together with the nitrogen atom to which they are attached form an optionally substituted monocyclic 5- or 6-membered heterocyclic ring;
Ar1 is -1 ,3-phenylene or -1 ,4-phenylene;
R is hydrogen or methyl;
one of A and B is hydrogen and the other is a group -Z-Ar2;
-Z- is -C(=O)-NH- , -NH-CO=O)-, -C(=O)-N(-CH3)-, or -N(-CH3)-C(=O)- ; and
Ar2 is halo- or Ci-C3 alkyl- substituted phenyl.
Specific compounds with which the invention is concerned include those of the Examples, particularly those exemplified compounds which have structure (II) above.
According to a further aspect of the invention, there is provided for use in therapy a compound of formula (I).
According to a further aspect of the invention, there is provided the use of a compound of formula (I) in the manufacture of a medicament for the treatment of a disorder mediated by Aurora Kinases.
According to a further aspect of the present invention there is provided a method of treatment of a disorder mediated by Aurora Kinases comprising
administration to a subject in need of such treatment an effective dose of the compound of formula (I), or a pharmaceutically acceptable salt or prodrug thereof.
The present invention is particularly directed to a hyperproliferative disease such as cancer, wherein the cancer is colorectal, breast, lung, prostate, bladder, renal or pancreatic cancer, or leukaemia or lymphoma.
The present invention may be employed in respect of a human or animal subject, more preferably a mammal, more preferably a human subject.
As used herein, the term "treatment" as used herein includes prophylactic treatment.
The compound of formula (I) may be used in combination with one or more additional drugs useful in the treatment of the disorders mentioned above, the components being in the same formulation or in separate formulations for administration simultaneously or sequentially.
It will be understood that the specific dose level for any particular patient will depend upon a variety of factors including the activity of the specific compound employed, the age, body weight, general health, sex, diet, time of administration, route of administration, rate of excretion, drug combination and the causative mechanism and severity of the particular disease undergoing therapy. In general, a suitable dose for orally administrable formulations will usually be in the range of 0.1 to 3000 mg, once, twice or three times per day, or the equivalent daily amount administered by infusion or other routes. However, optimum dose levels and frequency of dosing will be determined by clinical trials as is conventional in the art.
The compounds with which the invention is concerned may be prepared for administration by any route consistent with their pharmacokinetic properties. The orally administrable compositions may be in the form of tablets, capsules, powders, granules, lozenges, liquid or gel preparations, such as oral, topical,
or sterile parenteral solutions or suspensions. Tablets and capsules for oral administration may be in unit dose presentation form, and may contain conventional excipients such as binding agents, for example syrup, acacia, gelatin, sorbitol, tragacanth, or polyvinyl-pyrrolidone; fillers for example lactose, sugar, maize-starch, calcium phosphate, sorbitol or glycine; tabletting lubricant, for example magnesium stearate, talc, polyethylene glycol or silica; disintegrants for example potato starch, or acceptable wetting agents such as sodium lauryl sulphate. The tablets may be coated according to methods well known in normal pharmaceutical practice. Oral liquid preparations may be in the form of, for example, aqueous or oily suspensions, solutions, emulsions, syrups or elixirs, or may be presented as a dry product for reconstitution with water or other suitable vehicle before use. Such liquid preparations may contain conventional additives such as suspending agents, for example sorbitol, syrup, methyl cellulose, glucose syrup, gelatin hydrogenated edible fats; emulsifying agents, for example lecithin, sorbitan monooleate, or acacia; non-aqueous vehicles (which may include edible oils), for example almond oil, fractionated coconut oil, oily esters such as glycerine, propylene glycol, or ethyl alcohol; preservatives, for example methyl or propyl p-hydroxybenzoate or sorbic acid, and if desired conventional flavouring or colouring agents.
For topical application to the skin, the drug may be made up into a cream, lotion or ointment. Cream or ointment formulations which may be used for the drug are conventional formulations well known in the art, for example as described in standard textbooks of pharmaceutics such as the British Pharmacopoeia.
The active ingredient may also be administered parenterally in a sterile medium. Depending on the vehicle and concentration used, the drug can either be suspended or dissolved in the vehicle. Advantageously, adjuvants such as a local anaesthetic, preservative and buffering agents can be dissolved in the vehicle.
There are multiple synthetic strategies for the synthesis of the compounds (I) with which the present invention is concerned, but all rely on known
chemistry, known to the synthetic organic chemist. Thus, compounds according to formula (I) can be synthesised according to procedures described in the standard literature and are well-known to the one skilled in the art. Typical literature sources are "Advanced organic chemistry", 4th Edition (Wiley), J March, "Comprehensive Organic Transformation", 2nd Edition (Wiley), R.C. Larock , "Handbook of Heterocyclic Chemistry", 2nd Edition (Pergamon), A. R. Katritzky), review articles such as found in "Synthesis", "Ace. Chem. Res." , "Chem. Rev", or primary literature sources identified by standard literature searches online or from secondary sources such as "Chemical Abstracts" or "Beilstein". Such literature methods include those of the preparative Examples herein, and methods analogous thereto.
Suitable routes to compounds of formula (I) are shown below in schemes 1 to 7.
Scheme 1
Scheme 2
Examples
The following examples illustrate the preparation and activities of specific compounds of the invention.
Example 1
1.1 Synthesis of S-amino-δ-β-hydroxymethyl-phenyO-pyrazine^-carboxylic acid methyl ester
To a solution of 3-amino-6-bromo-pyrazine-2-carboxylic acid methyl ester (3g, 12.9 mmol) in DMF (40ml) was added 3-(hydroxymethyl)benzoic acid (2.16g, 14.22 mmol) followed by Et3N (2.7ml, 19.39 mmol) under nitrogen at room temperature. The mixture was stirred for 10 min before adding 1 ,1'-bis[dit- butylphosphino)ferrocene]paliadium chloride (0.25g, 0.039 mmol) and stirred overnight at 900C. The cooled reaction mixture was condensed. The residue dissolved in THF-EtOAc mixture (200ml, 1 :1), filtered to remove catalyst and evaporated. The filtrated was washed with brine, dried (MgSO4) and
condensed. The resultant brown solid residue was subjected to flash column chromatography on silica eluting gradient of hexane to (3:1 , v/v) ethyl acetate and hexane to give title compound (1.61g, 48%) as a yellow/orange solid; LC/MS: Rt 1.74 (Method A) [M+H]+ 260.
1.2 Synthesis of 3-amino-6-[3-(tert-butyldimethylsilanyloxymethyl)-phenyl]- pyrazine-2-carboxylic acid methyl ester
To a solution of 3-amino-6-(3-hydroxymethyl-phenyl)-pyrazine-2-carboxylic acid methyl ester (1.61g, 6.21 mmol) in DMF (20ml) was added tert- butyldimethylsilyl chloride (1.12g, 7.46 mmol) followed by imidazole (0.51g, 7.46 mmol) under nitrogen at 00C. The mixture was allowed to warm to room temperature and stirred for 3 hr. The reaction mixture was condensed. The residue dissolved in EtOAc (200ml), washed with brine, dried (MgSO4) and condensed. The resultant solid residue was subjected to flash column chromatography on silica eluting gradient of hexane to (1 :4, v/v) ethyl acetate and hexane to give title compound (2.09g, 90%) as a yellow solid; LC/MS: Rt 2.88 (Method A) [M+H]+ 374; 1H-NMR (400MHz, D6 DMSO) g 0.10 (6H, s), 0.93 (9H, s), 3.89 (3H, s), 4.79 (2H1 s), 7.31 (1 H, m), 7.45 (3H, m), 7.87(1 H, m), 7.98 (1H, s broad), 8.88 (1 H, s).
1.3 Synthesis of 3-amino-6-[3-(tert-butyl-dimethyl-silanyloxymethyl)-phenyl]- pyrazine-2-carbaldehyde
To a solution of 3-amino-6-[3-(tert-butyldimethylsilanyloxymethyl)-phenyl]- pyrazine-2-carboxylic acid methyl ester (2.09g, 5.6 mmol) in THF (30ml) was added LiAIH4 powder (0.64g, 16.8 mmol) in portion at 00C. The mixture was allowed to warm to ambient temperature and stirred for 3 hr. The reaction mixture was cooled and quenched with 2N (aq) NaOH (2-3 drops) and water until reaction subsided. The solution was extracted with ethyl acetate, filtered, washed with brine, dried (MgSO4) and condensed. The crude residue was suspended in DME (30ml), MnO2 (9.7g, 11.2 mmol) was added and heated at 950C for 2 hr. The reaction mixture was filtered through a plug of celite and condensed. The resultant solid residue was subjected to flash column chromatography on silica eluting gradient of hexane to (1 :4, v/v) ethyl acetate and hexane to give title compound (0.83g, 43%) as a yellow solid; LC/MS: Rt 2.93 (Method A) [M+H]+ 344; ; 1H-NMR (400MHz, D6 DMSO) D 0.10 (6H, s), 0.93 (9H, s), 4.80 (2H, s), 7.35 (1 H, m), 7.46 (1H, m), 7.81 (2H, s broad), 7.92 (1 H, m), 8.01 (1 H, s broad), 8.95 (1 H, s), 10.00 (1H, s).
1.4 Synthesis of N-(3-fluoro-phenyl)-3,4-dinitro-benzamide
A mixture of 3,4-dinitrobenzoic acid (10g, 47.14 mmol) and thionyl chloride (17.2ml, 235 mmol) was heated at 800C overnight. The cooled reaction mixture was condensed; toluene was added (10ml) and removed in vacuum. The residue was dissolved in DCM (10ml) and 3-fluoroanaline (1.09ml, 11.3
mmol) in DCM (5ml) was added dropwise at 00C. The mixture was allowed to warm to ambient temperature and stirred for 4 hr. The reaction mixture was condensed. The residue dissolved in EtOAc (200ml), washed with 1 N (aq) HCI (100 ml), sat. (aq) NaHCO3 (100ml), brine, dried (MgSO4) and condensed. The resultant solid residue was triturated with diethyl ether to give title compound (8.69g, 60%) as a yellow solid; 1H-NMR (400MHz, D6 DMSO) D 7.01 (1 H, m), 7.44 (1 H, m), 7.54 (1 H, m), 7.73 (1 H, m), 8.42(1 H, m), 8.48 (1 H, m), 8.73 (1 H, d), 10.89 (1 H, s broad).
1.5 Synthesis of 3,4-diamino-N-(3-fluoro-phenyl)-benzamide
A mixture of N-(3-fluoro-phenyl)-3,4-dinitro-benzamide (8.69g, 28.47 mmol) and 5% Pt/C (0.9g, catalytic) in DMF (5 ml) was agitated under an atmosphere of hydrogen at room temperature for 8 hr. The reaction mixture was filtered to remove catalyst and evaporated. The resultant solid residue was subjected to flash column chromatography on silica eluting gradient of hexane to (4:1 , v/v) ethyl acetate and hexane to give title compound (4.1g, 59%) as a pale brown solid; LC/MS: Rt 1.76 (Method A) [M+H]+ 246; 1H-NMR (400MHz, D6 DMSO) P 4.66 (2H, s broad), 5.15 (2H, s broad), 6.53 (1 H, d), 6.83 (1 H, m), 7.12 (2H, m), 7.31 (1 H, m), 7.52 (1 H, m), 7.72 (1 H, m), 9.89 (1H, s broad).
1.6 Synthesis of 2-[3-amino-6-(3-formyl-phenyl)-pyrazin-2-yl]-1 H- benzoimidazole-5-carboxylic acid (3-fluoro-phenyl)-amide
A suspension of 3-amino-6-[3-(tert-butyl-dimethyl-silanyloxymethyl)-phenyl]- pyrazine-2-carbaldehyde (0.4g, 1.17 mmol) and 3,4-diamino-N-(3-fluoro- phenyl)-benzamide (0.85g, 4.66 mmol) in acetonitrile (10ml) was added sodium bisulphite (0.24g, 2.34 mmol) and heated at 90°C overnight. More sodium bisulphite was added (0.24g, 2.34 mmol) and the mixture heated at reflux for further 24 hr. The cooled reaction mixture was diluted with EtOAc (20ml) and washed with 2N (aq) HCI (20ml). The separated organic layer was washed with brine, dried (MgSO^ and condensed. The crude orange solid was suspended in DME (30ml), MnO2 (1.02g, 11.7 mmol) was added and heated at 95°C for 6 hr. The reaction mixture was filtered through a plug of celite and condensed. The resultant solid residue was subjected to flash column chromatography on silica eluting gradient of hexane to (3:1 , v/v) ethyl acetate and hexane to give title compound (0.09g, 17%) as a yellow/orange solid; LC/MS: Rt 2.60 (Method A) [M+H]+ 453.
1.7 Synthesis of 2-{3-amino-6-[3-(3-hydroxymethyl-piperidin-1-ylmethyl)- phenyl]-pyrazin-2-yi}-1 H-benzoimidazole-5-carboxylic acid (3-fluoro-phenyl)- amide
To a suspension of 2-[3-amino-6-(3-formyl-phenyl)-pyrazin-2-yl]-1 H- benzoimidazole-5-carboxylic acid (3-fluoro-phenyl)-amide (0.03g, 0.06 mmol) in THF (5ml) was added 3-piperidinemethanol (0.023g, 0.20 mmol) followed by sodium triacetoxyborohydride (0.042g, 0.20 mmol) at room temperature. The reaction was stirred for 4 hr, diluted with EtOAc (4ml), washed with saturated NaHCO3 (5ml), brine, dried (MgSO-O and condensed. The resultant solid residue was subjected to flash column chromatography on silica eluting gradient of DCM to (5%, v/v) methanol and DCM to give title compound (0.012g, 32%) as a yellow solid; LC/MS: Rt 1.89 (Method A) [M+H]+ 552.
Example 2
2-[3-Amino-6-(3-{[ethyl-(2-hydroxy-ethyl)-amino]-methyl}-phenyl)-pyrazin-2-yl]- 1 H-benzoimidazole-5-carboxylic acid (3-fluoro-phenyl)-amide
2-[3-Amino-6-(3-{[ethyl-(2-hydroxy-ethyl)-amino]-methyl}-phenyl)-pyrazin-2-yl]- 1 H-benzoimidazole-5-carboxylic acid (3-fluoro-phenyl)-amide was prepared by methods analogous to Example 1 ; LC/MS: Rt 1.91 (Method A) [M+H]+ 526.
Example 3
2-[3-Amino~6-(3-piperidin-1-ylmethyl-phenyl)~pyrazin-2-yl]-1 H- benzoimidazole-5-carboxylic acid (3-fluoro-phenyl)-amide
2-[3-Amino-6-(3-piperidin-1-yImethyl-phenyl)-pyrazin-2-yl]-1 H- benzoimidazole-5-carboxylic acid (3-fluoro-phenyl)-amide was prepared by methods analogous to reference Example 7; LC/MS: Rt 1.95 (Method A) [M+H]+ 522.
Example 4
4.1 Synthesis of 3-amino-6-{3-[2-(tert-butyl-dimethyl-silanyloxy)-ethyl]-phenyl}- pyrazine-2-carboxylic acid
A suspension of S-amino-β-bromo-pyrazine^-carboxylic acid (0.5g, 2.3 mmol) and 3-[2-(tert-butyl-dimethyl-silanyloxy)-ethyl]-phenylboronic acid (patent WO 2003076422, 1.28g, 4.6 mmol) in MeCN (20ml) was treated with K2CO3 (3.8g, 27.5 mmol) in H2O (5ml) under nitrogen at room temperature. The mixture was stirred for 10 min before adding bis(triphenylphosphine)palladium dichloride (0.08g, catalytic) and stirred at 9O0C for 3 hr. The cooled reaction mixture was dilute with H2O (20ml), basified to ph4, filtered to remove catalyst and evaporated. The residue dissolved in DCM (200ml), washed with brine, dried (MgSO4) and condensed. The solid residue was subjected to flash column chromatography on silica eluting gradient of hexane to (2:1 , v/v) ethyl
acetate and hexane to give title compound (0.38g, 44%) as a yellow solid; LC/MS: Rt 2.78 (Method A) [M+H]+ 374.
4.2 Synthesis of 2-{3-amino-6-[3-(2-hydroxy-ethyl)-phenyl]-pyrazin-2-yl}-1 H- benzoimidazole-5-carboxylic acid (3-fluoro-phenyl)-amide
A solution of 3-amino-6-{3-[2-(tert-butyl~dimethyl-silanyloxy)-ethyl]-phenyl}- pyrazine-2-carboxylic acid (0.38g, 1.02 mmol) and 3,4-diamino-N-(3-fluoro- phenyl)-benzamide (0.262g, 1.07 mmol) in THF (20ml) was treated with HOBt (0.179g, 1.32 mmol), EDCI (0.253g, 1.32 mmol) and DIPEA (0.35ml, 2.03 mmol) under nitrogen at room temperature. The reaction mixture was stirred overnight and condensed. The residue dissolved in acetic acid (20ml) and heated at 13O0C for 5 hr. HCI (37% wt, 4ml) was added and the mixture stirred at 1300C for further 2 hr. The cooled reaction mixture was condensed, dissolved in H2O (20ml) and basified to ph7. The solution was extracted with EtOAc-THF mixture (100ml, 3:1), washed with brine, dried (MgSO4) and condensed. The resultant orange oil was dissolved in methanol (10ml) and treated with 1 M (aq) K2CO3 (2ml) at room temperature. The reaction mixture was allowed to stir at room temperature for 3 hr and condensed. The residue dissolved in THF-EtOAc mixture (50ml, 2:1), washed with brine, dried (MgSO4) and condensed. The solid residue was subjected to flash column chromatography on silica eluting gradient of hexane to (3:1 , v/v) ethyl acetate and hexane to give title compound (0.3Og, 63%) as a yellow solid; LC/MS: Rt 2.45 (Method A) [M+H]+ 469.
4.3 Synthesis of 2~{3-amino-6-[3-(2-oxo-ethyl)-phenyl]-pyrazin-2-yl}-1 H- benzoimidazole-5-carboxylic acid (3-fluoro-phenyl)-amide
A suspension of 2-{3-amino-6-[3-(2-hydroxy-ethyl)-phenyl]-pyrazin-2-yl}-1 H- benzoimidazole-5-carboxylic acid (3-fluoro-phenyl)-amide (0.29g, 0.62 mmol) in THF (20ml) was treated with IBX (0.52g, 1.86 mmol) and heated at 900C for 2 hr. The cooled reaction mixture was filtered and condensed. The solid residue was subjected to flash column chromatography on silica eluting gradient of hexane to (3:1 , v/v) ethyl acetate and hexane to give title compound (0.14g, 48%) as a yellow solid; LC/MS: Rt 2.45 (Method A) [M+H]+ 469; TLC Rt 0.66 (EtOAc-hexane, 2:1).
4.4 2-[3-Amino-6-(3-{2-[ethyl-(2-hydroxy-ethyl)-amino]-ethyl}-phenyl)-pyrazin- 2-yl]-1 H-benzoimidazole-5-carboxylic acid (3-fluoro-phenyl)-amide
2-[3-Amino-6-(3-{2-[ethyl-(2-hydroxy-ethyl)-amino]-ethyl}-phenyl)-pyrazin-2- yl]-1 H-benzoimidazole-5-carboxylic acid (3-fluoro-phenyl)-amide was prepared by methods analogous to Example 1 ; LC/MS: Rt 1.94 (Method A) [M+H]+ 540.
Example 5
2-(3-Amino-6-{3-[2-(4-hydroxymethyl-piperidin-1-yl)-ethyl]-phenyl}-pyrazin-2- yl)-1 H-benzoimidazole-5-carboxylic acid (3-fluoro-phenyl)-amide
2-(3-Amino-6-{3-[2-(4-hydroxymethyl-piperidin-1-yl)-ethyl]-phenyl}-pyrazin-2- yl)-1 H-benzoimidazole-5-carboxylic acid (3-fluorc-phenyl)-amide was prepared by methods analogous to reference Example 7; LC/MS: Rt 1.92 (Method A) [M+H]+ 566.
Example 6
2-(3-Amino-6-{3-[2-(3-hydroxymethyl-piperidin-1-yl)-ethyI]-phenyl}-pyrazin-2- yl)-1 H-benzoimidazole-5-carboxylic acid (3-fluoro-phenyl)-amide
2-(3-Amino-6-{3-[2-(3-hydroxymethyl-piperidin-1-yl)-ethyl]-phenyl}-pyrazin-2- yl)-1 H-benzoimidazole-5-carboxylic acid (3-fluoro-phenyl)-amide was prepared by methods analogous to reference Example 7; LC/MS: Rt 1.96 (Method A) [M+H]+ 566.
Examples 7 to 59 listed in the following table were prepared by methods analogous to Examples 1 to 6 above. All 59 compounds were tested for activity in kinase assays described below in the Assay section.
In the examples, characterization and/or purification were performed using standard spectroscopic and chromatographic techniques, including liquid chromatography-mass spectroscopy (LC-MS) and high performance liquid chromatography (HPLC), using the conditions described in methods A, B and C. NMR experiments were conducted on a Bruker DPX400 ultra shield NMR spectrometer in the specified solvent. Reactions carried out under microwave irradiation were conducted in a Smith Synthesizer.
LCMS Method A
Instrument: HP1100 Column: Luna 3 μm, C18(2), 30 mm x 4.6 mm i.d. from
Phenomenex
Temperature: 22 °C Solvents: A - Water + 10 mmol / L ammonium acetate + 0.08% (v/v) formic acid
B - 95% Acetonitrile-5% Solvent A + 0.08% (v/v) formic acid
Gradient:
Detection: UV detection at 230, 254 and 270 nm Mass Spec: HP1100 MSD, series A
Ionization was positive or negative ion electrospray
Molecular weight scan range was 120-1000
Method B
Instrument: Waters FractionLynx MS autopurification system Column: Luna 5 μm, C18(2), 100 mm x 21.2 mm i.d. from
Phenomenex
Temp: ambient Solvents: A- water + 0.08% (v/v) formic acid
B- 95% methanol-water + 0.08% (v/v) formic acid
Flow rate: 20 cm3 min~1
Gradient:
Detection: Photodiode array 210 to 400 nm Mass spec: MicroMass ZQ
Ionization was positive or negative ion electrospray
Molecular weight scan range was 150-1000
Collection: Triggered on selected mass ion
Method C
Instrument: Waters 2695 pump module and 2700 sample manager Column: Gemini 5μm, C18 110A, 30 mm x 2mm i.d. from Phenomenex. Pt no 00A-4435-B0
Temperature: 22 °C Solvents: A - Water + 10 mmol / ammonium formate + 0.08% (v/v) formic acid at pH 3.5 B - 100% Acetonitrile + 0.025% (v/v) formic acid
Injection Volume 5uL Gradient:
Detection: UV detection from 220 to 400nm ( 1 :3 split ) Mass Spec: Waters ZQ2000, M/z range 100 to 900
Assay Protocols
Aurora A
Assays for the Aurora A Kinase activity were carried out by monitoring the phosphorylation of a synthetic peptide, Kemptide (LRRASLG). The assay mixture containing the inhibitor, Aurora A enzyme, and peptide was mixed together in a microtiter plate in a final volume of 50μl and incubated for 30min at 3O0C. The assay mixture contained 0.01 mM unlabeled ATP, 0.01 μCi/μl 33P-γ-ATP, 0.2mM peptide, 0.1 mg/ml BSA, 7.5mM magnesium acetate, 0.04M MOPS, pH 7, 1mM EDTA. The reaction was stopped by adding 50μl of 5OmM phosphoric acid. 90μl of the mixture were transferred to a pre-wetted 96-well Multiscreen MAPHNOB filtration plate (Millipore) and filtered on a vacuum manifold. The filter plate was washed with 3 successive additions of
200μl 5OmM phosphoric acid and then with 100μl methanol. The filtration plate was dried for 10 min at 650C1 scintillant added and phosphorylated peptide quantified in a scintillation counter (Trilux, PerkinElmer).
Aurora B
Assays for the human Aurora B Kinase activity were carried out by monitoring the phosphorylation of a synthetic peptide, Paktide (RRRLSFEPG). The assay mixture containing the inhibitor, human Aurora B enzyme, and peptide was mixed together in a microtiter plate in a final volume of 50μl and incubated for 30min at 30°C. The assay mixture contained 0.01 mM unlabeled ATP, 0.01μCi/μl 33P-γ-ATP, 140μM peptide, 0.05% Brij 35, 5OmM magnesium chloride, 25OmM Hepes, pH 7.5, 5mM EGTA. The reaction was stopped by adding 50μl of 5OmM phosphoric acid. 90μl of the mixture were transferred to a pre-wetted 96-well Multiscreen MAPHNOB filtration plate (Millipore) and filtered on a vacuum manifold. The filter plate was washed with 3 successive additions of 200μl 5OmM phosphoric acid and then with 100μl methanol. The filtration plate was dried for 10 min at 650C, scintillant added and phosphorylated peptide quantified in a scintillation counter (Trilux, PerkinElmer).
All compounds tested in the above assays were found to have Aurora kinase inhibition in the range IC50 = 0.003 μM to 1 μM.
By way of illustration, the compound of Example 5 gave an IC50 versus Aurora A kinase of O.OδOμM and an IC50 versus Aurora B kinase of O.OOδμM.
Cellular responses to Aurora inhibition
Specific Aurora A inhibitors will arrest cells with a 4n DNA content (a phenotype also imposed by the inhibition of several other kinases). Compounds with substantial Aurora B inhibitory activity will promote mitotic exit without cell division. If these cells are capable of
replicating their DNA (which implies that various other kinases are not inhibited including Cdc7, CDK2 etc) then a peak of 8n cells will appear.
Flow Cytometry Assay
Fluorescence-activated cell-sorting (FACS) is a trademarked employed by Becton-Dickinson to describe their method of flow cytometry (FCM). FCM is a method for sorting a suspension of biological cells into two or more containers one cell at a time, based upon the specific light scattering and fluorescent characteristics of each cell. In this particular implementation the cells are not collected post sorting.
A flow cytometer operates by causing a fluid stream to pass single file through a beam of light usually generated by a laser. The photons of light emitted by the cells, following their interaction with the laser beam, are separated into constituent wavelengths by a series of filters and mirrors. This separated light falls upon individual detectors that generate electrical impulses or analogue signals proportional to the amount of light striking the detectors. Each analogue signal is converted to a digital signal which is accumulated in a frequency distribution or histogram (see figure below).
It is possible to deduce various facts about the physical and chemical structure of each particle from the data generated. FCM is commonly used to quantify the volume and morphological complexity of cells, enzymatic activity and the quantification and measurement of DNA degradation. However in this case the assay has been designed for DNA cell cycle analysis using Propidium Iodide staining of the DNA.
HCT-116 cells are grown and maintained by methods that will be familiar to those skilled in the art. For flow cytometry cells are counted and split into a 24-well plate at 30000 cells/well. The next day putative Aurora inhibitors are added at a range of appropriate concentrations (usually tripling dilution series are used). 48 hours later, floating cells are removed, then combined with the corresponding adherent cells that released by treatment with trypsin using methods familiar to those skilled in the art. The combined cell population is pelleted by 5 minutes centrifugation at 200 x g, washed with phosphate buffered saline, then resuspended in a solution containing (50 ug/ml propidium iodide and 0.5 mg/ml RNAase A). 1 hour of incubation at 37 C is sufficient for the digestion of cellular RNAs enabling the amount of propidium iodide associated with cells to be proportional to their DNA content. Samples are then read on a BD FACSArray with the amount of propidium iodine staining being measured for each cell; this yields a fluorescence histogram that plots the number of cells with a particular fluorescence against propidium iodide fluorescence. Untreated cells are bimodally distributed on such a fluorescence histogram with a large peak representing cells with a 2n DNA content (G 1 cells) and a smaller peak composed of cells with approximately double the fluorescence of the first peak representing cells with a 4n DNA content (cells in G2 and mitosis); cells with an intermediate fluorescence represent cells in S phase.
Treatment with a pure Aurora A inhibitor is predicted to lead to a sharp increase in the number of cells with a 4n DNA content (though this was not observed for our compounds). Treatment of cells with an Aurora B inhibitor leads to failed cell division, followed by an attempt to re-replicate the genome which leads to the appearance of an 8n peak. Note that the co- inhibition of kinases required for replication will prevent the appearance of the 8n peak and the co-inhibition of kinases required for survival under the culture conditions of the HCT116 cells will result in the appearance of apoptotic cells, which due to the activation of nucleases, will have a DNA content of < 2n. Therefore the range of doses that leads to the appearance of a peak of 8n cells, without the induction of a major sub 2n peak can be used as an indication of the dose range at which an inhibitor imposes an Aurora B blockade without confounding effects on other targets.
Example 27 Example 5 Example 40
Claims
1. A compound of formula (I) or a pharmaceutically acceptable salt, hydrate or solvate thereof
(I)
wherein
Ri, R2, R3, R4 and R5 are independently selected from hydrogen, hydroxy, C1- C3 alkyl, fluoro(C1-C3)alkyl, hydroxy(C1-C3)alkyl, C1-C3 alkoxy, fluoro(C1- C3)alkoxy, hydroxy(C1-C3)alkoxy, -N(R6)-R7,- AIk-N(R6)-R7, -0-AIk-N(R6)-R7, - C(=O)OH, carboxy(C1-C3)alkyl, or -C(=O)-NH-R8;
R6 is hydrogen, C1-C3 alkyl, or fluoro(C1-C3)alkyl, and
R7 is C1-C3 alkyl, hydroxy-(C1 -C6)alkyl, hydroxy-(C1-C6)alkyl substituted on the alkyl portion by phenyl, C1-C3 alkoxy-(C1-C3)alkyl, halo(C1-C4)alkyl, or C3-C6 cycloalkyl;
or R6 and R7 taken together with the nitrogen atom to which they are attached form an optionally substituted monocyclic 5- or 6-membered heterocyclic ring;
R8 is selected from hydrogen, C1-C3 alkyl, fluoro(C1-C3)alkyl, or a radical of formula -AIk-N(R9)-Ri0; Rg and R10 are independently selected from hydrogen, C-1-C3 alkyl, or fluoro(Ci-C3)alkyl;
or Rg and R10 taken together with the nitrogen atom to which they are attached form an optionally substituted monocyclic 5- or 6-membered heterocyclic ring;
-AIk- is a divalent (C-i-C-4)alkylene radical;
R is hydrogen or C1-C3 alkyl;
one of A and B is hydrogen and the other is a group -Z-Ar;
-Z- is -C(=O)-NH- , -NH-C(=O)-, -C(=O)-N(-CH3)-, or -N(-CH3)-C(=O)- ; and
Ar is aryl or heteroaryl, optionally substituted with one or more halogen atoms, C1-C3 alkyl radicals or trifluoromethyl radicals.
2. A compound as claimed in claim 1 wherein Ri to R5 are independently selected from hydrogen, hydroxy, hydroxy(Ci-C3)alkyl, hydroxy(Ci-C3)alkoxy, -C(=O)OH, carboxy(Ci-C3)alkyl, - AIk-N(Re)-R7, -O-Alk-N(R6)-R7 or -C(=O)- NH-R8.
3. A compound as claimed in claim 1 or claim 2 wherein Ri to R5 are independently selected from hydrogen, hydroxymethyl, hydroxymethoxy, or 2- hydroxyethyl.
4. A compound as claimed in claim 1 or claim 2 wherein Re is hydrogen, methyl or ethyl, and R7 is methyl, ethyl, 2-hydroxyethyl, 2-methoxyethyl, 2,2,2- trifluoroethyl, cyclopentyl, -CH(JPr)-CH2-OH Or-CH(Ph)-CH2-OH.
5. A compound as claimed in claim 1 or claim 2 wherein Re and R7 taken together with the nitrogen atom to which they are attached form an optionally substituted monocyclic 6-membered heterocyclic ring.
6. A compound as claimed in claim 5 wherein R6 and R7 taken together with the nitrogen atom to which they are attached form optionally substituted morpholinyl, piperidinyl or piperazinyl.
7. A compound as claimed in claim 5 or claim 6 wherein Re and R7 taken together with the nitrogen atom to which they are attached form morpholin-4- yl, 1-methyl-piperazin-4-yl, or piperidin-1-yl optionally substituted by hydroxymethyl, fluoro, hydroxy, methyl, 2-hydroxyethyl, or trifluoromethyl.
8. A compound as claimed in claim 7 wherein R6 and R7 taken together with the nitrogen atom to which they are attached form 1-fluoro-piperidin-3-yl, 1-hydroxy-piperidin-3-yl, 1-hydroxymethyl-piperidin-3-yl, 1-hydroxymethyl- piperidin-4-yl, i-methyl-piperidin-3-yl, 1-(2-hydroxyethyl)~piperidin~3-yl, or 1- trifluoromethyl-piperidin-3-yl.
9. A compound as claimed in claim 1 or claim 2 wherein R8 is a radical of formula -AIk-N(Rg)-R10.
10. A compound as claimed in claim 9 wherein R9 and Rio taken together with the nitrogen atom to which they are attached form an optionally substituted monocyclic 5- or 6-membered heterocyclic ring.
11. A compound as claimed in claim 10 wherein R9 and Rio taken together with the nitrogen atom to which they are attached form optionally substituted piperidinyl or pyrrolidinyl.
12. A compound as claimed in claim 10 or claim 11 wherein R9 and Rio taken together with the nitrogen atom to which they are attached form piperidin-1-yl, 1-methyl-piperidin-2-yl, 1-hydroxy-piperidin-4-yl, or 1-ethyl- pyrrolidin-2-yl.
13. A compound as claimed in any of the preceding claims wherein AIk is methylene, -(CH2^- or -(CH2)3-.
14. A compound as claimed in any of the preceding claims wherein R is hydrogen.
15. A compound as claimed in any of claims 1 to 13 wherein R is methyl.
16. A compound as claimed in any of the preceding claims wherein -Z- is - C(=O)-NH-.
17. A compound as claimed in any of claims 1 to 15 wherein -Z- is -NH- C(O)-.
18. A compound as claimed in any of the preceding claims wherein Ar is phenyl, 2-fluorophenyl, 3-fluorophenyl, 2,3-difluorophenyl, 2,4-difluorophenyl, 3,4-difluorophenyl, 3,5-difluorophenyl, 3-chlorophenyl, 3-methylphenyl, or 3- trifluoromethylphenyl.
19. A compound as claimed in any of claims 1 to 17 wherein Ar is pyridyl or N-oxido-pyridyl optionally substituted with one or more halogen atoms, C1-C3 alkyl radicals or trifluoromethyl radicals.
20. A compound of formula (II) or a pharmaceutically acceptable salt, hydrate or solvate thereof
(II)
wherein R1 is hydrogen, hydroxy, hydroxy(C1-C3)alkyl, -C(=O)OH, carboxy(Cr C3)alkyl, hydroxy(Ci-C3)alkoxy, a radical of formula -(CH2)n-N(R3)-R4 wherein n is 1 or 2, a radical of formula -O-(CH2)n-N(R3)-R4 wherein n is 1 or 2, or a radical of formula -C(=O)-NH-(CH2)p-N(R5)-R6 wherein p is 1 , 2 or 3;
R3 is hydrogen or Ci-C3 alkyl, and
R4 is C1-C3 alkyl, hydroxy-(Ci-C6)alkyl, hydroxy-(Ci-C6)alkyl substituted on the alkyl portion by phenyl, Ci-C3 alkoxy-(Ci-C3)alkyl, halo CrC4 alkyl, or C3-C6 cycloalkyl;
or R3 and R4 taken together with the nitrogen atom to which they are attached form an optionally substituted monocyclic 6-membered heterocyclic ring;
R5 and Re taken together with the nitrogen atom to which they are attached form an optionally substituted monocyclic 5- or 6-membered heterocyclic ring;
Ari is -1 ,3-phenylene or -1 ,4-phenylene;
R is hydrogen or methyl;
one of A and B is hydrogen and the other is a group -Z-Ar2;
-Z- is -C(=O)-NH- , -NH-CO=O)-, -C(=O)-N(-CH3)-, or -N(-CH3)-C(=O)- ; and
Ar2 is halo- or Ci-C3 alkyl- substituted phenyl.
21. A compound as claimed in claim 20 wherein Ri is hydrogen.
22. A compound as claimed in claim 20 wherein Ri is hydroxy.
23. A compound as claimed in claim 20 wherein Ri is hydroxy(Ci-C3)alkyl.
24. A compound as claimed in claim 20 wherein Ri is -C(=O)OH.
25. A compound as claimed in claim 20 wherein Ri is carboxy(Ci-C3)alkyl.
26. A compound as claimed in claim 20 wherein Ri is -CH2-N(Rs)-R4.
27. A compound as claimed in claim 20 wherein Ri is -(C Ha)2-N(Rs)-R4.
28. A compound as claimed in claim 20 wherein Ri is -O-CH2-N(R3)-R4.
29. A compound as claimed in claim 20 wherein Ri is -O-(CH2)2-N(R3)-R4.
30. A compound as claimed in claim 20 wherein Ri is -C(=O)-NH-(CH2)P- N(R5)-Re and p is 1 , 2 or 3.
31. A compound as claimed in claim 20 wherein Ri is hydroxymethyl, hydroxymethoxy, or 2-hydroxyethyl.
32. A compound as claimed in claim 20 or claims 26 to 29 wherein R3 is hydrogen, methyl or ethyl, and R4 is methyl, ethyl, 2-hydroxyethyl, 2- methoxyethyl, 2,2,2-trifluoroethyl, cyclopentyl, -CH(JPr)-CH2-OH or-CH(Ph)- CH2-OH.
33. A compound as claimed in claim 20 or claims 26 to 29 wherein R3 and R4 taken together with the nitrogen atom to which they are attached form morpholin-4-yl, or piperidin-1-yl optionally substituted by hydroxymethyl, fluoro, hydroxy, methyl, 2-hydroxyethyl, or trifluoromethyl.
34. A compound as claimed in claim 33 wherein R3 and R4 taken together with the nitrogen atom to which they are attached form 1 -fluoro-piperidin-3-yl, 1-hydroxy-piperidin-3-yl, 1-hydroxymethyl-piperidin-3-yl, 1 -hydroxy methyl- piperidin-4-yl, 1-methyl-piperidin-3-yl, 1-(2-hydroxyethyl)-piperidin-3-yl, or 1- trifluoromethyl-piperidin-3-yl.
35. A compound as claimed in claim 20 or claim 30 wherein R5 and R6 taken together with the nitrogen atom to which they are attached form an optionally substituted monocyclic 5- or 6-membered heterocyclic ring.
36. A compound as claimed in claim 35 wherein R5 and R6 taken together with the nitrogen atom to which they are attached form optionally substituted piperidinyl or pyrrolidinyl.
37. A compound as claimed in claim 35 or claim 36 wherein R5 and R6 taken together with the nitrogen atom to which they are attached form piperidin-1-yl, 1-methyl-piperidin-2-yl, 1-hydroxy-piperidin-4-yl, or 1-ethyl- pyrrolidin-2-yl.
38. A compound as claimed in any of claims 20 to 37 wherein Ar2 is phenyl, 2-fluorophenyl, 3-fluorophenyl, 2,3-difluorophenyl, 2,4-difluorophenyl, 3,4-difluorophenyl, 3,5-difluorophenyl, 3-chlorophenyl, 3-methylphenyl, or 3- trifluoromethylphenyl.
39. A pharmaceutical composition comprising a compound as claimed in any of the preceding claims and a pharmaceutically acceptable carrier.
40. The use of a compound as claimed in any of the preceding claims in the preparation of a composition for the treatment of conditions responsive to inhibition of Aurora Kinase activity.
41. A method of treatment of a mammal suffering from a condition responsive to inhibition of Aurora Kinase activity, comprising administering to the mammal an amount of a compound as claimed in any of claims 1 to 38 effective to inhibit Aurora Kinase activity in the mammal.
42. The use as claimed in claim 40 or a method as claimed in claim 41 wherein the condition responsive to inhibition of Aurora Kinase activity is a hyperproliferative disease such as cancer.
43. The use or method as claimed in claim 42 wherein the cancer is colorectal, breast, lung, prostate, bladder, renal or pancreatic cancer, or leukaemia or lymphoma.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB0619342.9A GB0619342D0 (en) | 2006-09-30 | 2006-09-30 | New chemical compounds |
GB0619342.9 | 2006-09-30 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2008038010A1 true WO2008038010A1 (en) | 2008-04-03 |
Family
ID=37435006
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/GB2007/003687 WO2008038010A1 (en) | 2006-09-30 | 2007-09-28 | Pyrazine derivatives and their use in therapy |
Country Status (2)
Country | Link |
---|---|
GB (1) | GB0619342D0 (en) |
WO (1) | WO2008038010A1 (en) |
Cited By (37)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2009007390A2 (en) * | 2007-07-09 | 2009-01-15 | Astrazeneca Ab | 2-pyraz inylbenz imidazole derivatives as receptor tyrosine kinase inhibitors |
WO2009024825A1 (en) * | 2007-08-21 | 2009-02-26 | Astrazeneca Ab | 2-pyrazinylbenzimidazole derivatives as receptor tyrosine kinase inhibitors |
US8017611B2 (en) | 2007-10-25 | 2011-09-13 | Astrazeneca Ab | Pyridine and pyrazine derivatives -083 |
US8410112B2 (en) | 2008-11-10 | 2013-04-02 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of ATR kinase |
US8623869B2 (en) | 2010-06-23 | 2014-01-07 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of ATR kinase |
US8765751B2 (en) | 2011-09-30 | 2014-07-01 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of ATR kinase |
US8822469B2 (en) | 2011-06-22 | 2014-09-02 | Vertex Pharmaceuticals Incorporated | Pyrrolo[2,3-B]pyrazines useful as inhibitors of ATR kinase |
US8841337B2 (en) | 2011-11-09 | 2014-09-23 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of ATR kinase |
US8841308B2 (en) | 2008-12-19 | 2014-09-23 | Vertex Pharmaceuticals Incorporated | Pyrazin-2-amines useful as inhibitors of ATR kinase |
US8841450B2 (en) | 2011-11-09 | 2014-09-23 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of ATR kinase |
US8841449B2 (en) | 2011-11-09 | 2014-09-23 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of ATR kinase |
US8846917B2 (en) | 2011-11-09 | 2014-09-30 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of ATR kinase |
US8846686B2 (en) | 2011-09-30 | 2014-09-30 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of ATR kinase |
US8846918B2 (en) | 2011-11-09 | 2014-09-30 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of ATR kinase |
US8853217B2 (en) | 2011-09-30 | 2014-10-07 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of ATR kinase |
US8877759B2 (en) | 2011-04-05 | 2014-11-04 | Vertex Pharnaceuticals Incorporated | Aminopyrazines as ATR kinase inhibitors |
US8912198B2 (en) | 2012-10-16 | 2014-12-16 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of ATR kinase |
US8962631B2 (en) | 2010-05-12 | 2015-02-24 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of ATR kinase |
US8969356B2 (en) | 2010-05-12 | 2015-03-03 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of ATR kinase |
US9035053B2 (en) | 2011-09-30 | 2015-05-19 | Vertex Pharmaceuticals Incorporated | Processes for making compounds useful as inhibitors of ATR kinase |
US9062008B2 (en) | 2010-05-12 | 2015-06-23 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of ATR kinase |
US9096602B2 (en) | 2011-06-22 | 2015-08-04 | Vertex Pharmaceuticals Incorporated | Substituted pyrrolo[2,3-B]pyrazines as ATR kinase inhibitors |
US9096584B2 (en) | 2010-05-12 | 2015-08-04 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of ATR kinase |
US9309250B2 (en) | 2011-06-22 | 2016-04-12 | Vertex Pharmaceuticals Incorporated | Substituted pyrrolo[2,3-b]pyrazines as ATR kinase inhibitors |
US9334244B2 (en) | 2010-05-12 | 2016-05-10 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of ATR kinase |
US9340546B2 (en) | 2012-12-07 | 2016-05-17 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of ATR kinase |
US9630956B2 (en) | 2010-05-12 | 2017-04-25 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of ATR kinase |
US9663519B2 (en) | 2013-03-15 | 2017-05-30 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of ATR kinase |
US9670215B2 (en) | 2014-06-05 | 2017-06-06 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of ATR kinase |
US9791456B2 (en) | 2012-10-04 | 2017-10-17 | Vertex Pharmaceuticals Incorporated | Method for measuring ATR inhibition mediated increases in DNA damage |
US10160760B2 (en) | 2013-12-06 | 2018-12-25 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of ATR kinase |
US10478430B2 (en) | 2012-04-05 | 2019-11-19 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of ATR kinase and combination therapies thereof |
US10813929B2 (en) | 2011-09-30 | 2020-10-27 | Vertex Pharmaceuticals Incorporated | Treating cancer with ATR inhibitors |
US11046658B2 (en) | 2018-07-02 | 2021-06-29 | Incyte Corporation | Aminopyrazine derivatives as PI3K-γ inhibitors |
US11179394B2 (en) | 2014-06-17 | 2021-11-23 | Vertex Pharmaceuticals Incorporated | Method for treating cancer using a combination of Chk1 and ATR inhibitors |
US11464774B2 (en) | 2015-09-30 | 2022-10-11 | Vertex Pharmaceuticals Incorporated | Method for treating cancer using a combination of DNA damaging agents and ATR inhibitors |
US11926616B2 (en) | 2018-03-08 | 2024-03-12 | Incyte Corporation | Aminopyrazine diol compounds as PI3K-γ inhibitors |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2003055491A1 (en) * | 2001-12-24 | 2003-07-10 | Astrazeneca Ab | Substituted quinazoline derivatives as inhibitors of aurora kinases |
WO2004113324A1 (en) * | 2003-06-17 | 2004-12-29 | Astrazeneca Ab | Chinazoline derivatives as aurora kinase inhibitors |
WO2006032518A1 (en) * | 2004-09-24 | 2006-03-30 | F. Hoffmann-La Roche Ag | Novel phthalazinone derivatives, as aurora-a kinase inhibitors |
WO2006046735A1 (en) * | 2004-10-29 | 2006-05-04 | Banyu Pharmaceutical Co., Ltd. | Novel aminopyridine derivatives having aurora a selective inhibitory action |
-
2006
- 2006-09-30 GB GBGB0619342.9A patent/GB0619342D0/en not_active Ceased
-
2007
- 2007-09-28 WO PCT/GB2007/003687 patent/WO2008038010A1/en active Application Filing
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2003055491A1 (en) * | 2001-12-24 | 2003-07-10 | Astrazeneca Ab | Substituted quinazoline derivatives as inhibitors of aurora kinases |
WO2004113324A1 (en) * | 2003-06-17 | 2004-12-29 | Astrazeneca Ab | Chinazoline derivatives as aurora kinase inhibitors |
WO2006032518A1 (en) * | 2004-09-24 | 2006-03-30 | F. Hoffmann-La Roche Ag | Novel phthalazinone derivatives, as aurora-a kinase inhibitors |
WO2006046735A1 (en) * | 2004-10-29 | 2006-05-04 | Banyu Pharmaceutical Co., Ltd. | Novel aminopyridine derivatives having aurora a selective inhibitory action |
Non-Patent Citations (2)
Title |
---|
DITCHFIELD ET AL: "Aurora B couples chromosome alignment with anaphase by targeting BubR1, Mad2, and Cenp-E to kinetochores", THE JOURNAL OF CELL BIOLOGY, ROCKEFELLER UNIVERSITY PRESS, US, vol. 161, no. 2, 28 April 2003 (2003-04-28), pages 267 - 280, XP002271042, ISSN: 0021-9525 * |
HARRINGTON E A ET AL: "VX-680, A Potent and Selective Small-Molecule Inhibitor of the Aurora Kinases, Suppress Tumor Growth In Vivo", NATURE MEDICINE, NATURE PUBLISHING GROUP, NEW YORK, NY, US, vol. 10, no. 3, March 2004 (2004-03-01), pages 262 - 267, XP003014821, ISSN: 1078-8956 * |
Cited By (56)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2009007390A2 (en) * | 2007-07-09 | 2009-01-15 | Astrazeneca Ab | 2-pyraz inylbenz imidazole derivatives as receptor tyrosine kinase inhibitors |
WO2009007390A3 (en) * | 2007-07-09 | 2009-03-19 | Astrazeneca Ab | 2-pyraz inylbenz imidazole derivatives as receptor tyrosine kinase inhibitors |
WO2009024825A1 (en) * | 2007-08-21 | 2009-02-26 | Astrazeneca Ab | 2-pyrazinylbenzimidazole derivatives as receptor tyrosine kinase inhibitors |
US8017611B2 (en) | 2007-10-25 | 2011-09-13 | Astrazeneca Ab | Pyridine and pyrazine derivatives -083 |
US8410112B2 (en) | 2008-11-10 | 2013-04-02 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of ATR kinase |
US9701674B2 (en) | 2008-12-19 | 2017-07-11 | Vertex Pharmaceuticals Incorporated | Substituted pyrazines as ATR kinase inhibitors |
US9365557B2 (en) | 2008-12-19 | 2016-06-14 | Vertex Pharmaceuticals Incorporated | Substituted pyrazin-2-amines as inhibitors of ATR kinase |
US10961232B2 (en) | 2008-12-19 | 2021-03-30 | Vertex Pharmaceuticals Incorporated | Substituted pyrazines as ATR kinase inhibitors |
US10479784B2 (en) | 2008-12-19 | 2019-11-19 | Vertex Pharmaceuticals Incorporated | Substituted pyrazin-2-amines as inhibitors of ATR kinase |
US8841308B2 (en) | 2008-12-19 | 2014-09-23 | Vertex Pharmaceuticals Incorporated | Pyrazin-2-amines useful as inhibitors of ATR kinase |
US9062008B2 (en) | 2010-05-12 | 2015-06-23 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of ATR kinase |
US9630956B2 (en) | 2010-05-12 | 2017-04-25 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of ATR kinase |
US9334244B2 (en) | 2010-05-12 | 2016-05-10 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of ATR kinase |
US9096584B2 (en) | 2010-05-12 | 2015-08-04 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of ATR kinase |
US8962631B2 (en) | 2010-05-12 | 2015-02-24 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of ATR kinase |
US8969356B2 (en) | 2010-05-12 | 2015-03-03 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of ATR kinase |
US8623869B2 (en) | 2010-06-23 | 2014-01-07 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of ATR kinase |
US8877759B2 (en) | 2011-04-05 | 2014-11-04 | Vertex Pharnaceuticals Incorporated | Aminopyrazines as ATR kinase inhibitors |
US8822469B2 (en) | 2011-06-22 | 2014-09-02 | Vertex Pharmaceuticals Incorporated | Pyrrolo[2,3-B]pyrazines useful as inhibitors of ATR kinase |
US9309250B2 (en) | 2011-06-22 | 2016-04-12 | Vertex Pharmaceuticals Incorporated | Substituted pyrrolo[2,3-b]pyrazines as ATR kinase inhibitors |
US9096602B2 (en) | 2011-06-22 | 2015-08-04 | Vertex Pharmaceuticals Incorporated | Substituted pyrrolo[2,3-B]pyrazines as ATR kinase inhibitors |
US8853217B2 (en) | 2011-09-30 | 2014-10-07 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of ATR kinase |
US10822331B2 (en) | 2011-09-30 | 2020-11-03 | Vertex Pharmaceuticals Incorporated | Processes for preparing ATR inhibitors |
US8765751B2 (en) | 2011-09-30 | 2014-07-01 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of ATR kinase |
US9035053B2 (en) | 2011-09-30 | 2015-05-19 | Vertex Pharmaceuticals Incorporated | Processes for making compounds useful as inhibitors of ATR kinase |
US8846686B2 (en) | 2011-09-30 | 2014-09-30 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of ATR kinase |
US10813929B2 (en) | 2011-09-30 | 2020-10-27 | Vertex Pharmaceuticals Incorporated | Treating cancer with ATR inhibitors |
US10208027B2 (en) | 2011-09-30 | 2019-02-19 | Vertex Pharmaceuticals Incorporated | Processes for preparing ATR inhibitors |
US9862709B2 (en) | 2011-09-30 | 2018-01-09 | Vertex Pharmaceuticals Incorporated | Processes for making compounds useful as inhibitors of ATR kinase |
US8841337B2 (en) | 2011-11-09 | 2014-09-23 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of ATR kinase |
US8846917B2 (en) | 2011-11-09 | 2014-09-30 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of ATR kinase |
US8841450B2 (en) | 2011-11-09 | 2014-09-23 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of ATR kinase |
US8841449B2 (en) | 2011-11-09 | 2014-09-23 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of ATR kinase |
US8846918B2 (en) | 2011-11-09 | 2014-09-30 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of ATR kinase |
US11110086B2 (en) | 2012-04-05 | 2021-09-07 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of ATR kinase and combination therapies thereof |
US10478430B2 (en) | 2012-04-05 | 2019-11-19 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of ATR kinase and combination therapies thereof |
US9791456B2 (en) | 2012-10-04 | 2017-10-17 | Vertex Pharmaceuticals Incorporated | Method for measuring ATR inhibition mediated increases in DNA damage |
US8912198B2 (en) | 2012-10-16 | 2014-12-16 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of ATR kinase |
US9718827B2 (en) | 2012-12-07 | 2017-08-01 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of ATR kinase |
US10787452B2 (en) | 2012-12-07 | 2020-09-29 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of ATR kinase |
US11370798B2 (en) | 2012-12-07 | 2022-06-28 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of ATR kinase |
US9650381B2 (en) | 2012-12-07 | 2017-05-16 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of ATR kinase |
US10392391B2 (en) | 2012-12-07 | 2019-08-27 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of ATR kinase |
US11117900B2 (en) | 2012-12-07 | 2021-09-14 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of ATR kinase |
US9340546B2 (en) | 2012-12-07 | 2016-05-17 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of ATR kinase |
US9663519B2 (en) | 2013-03-15 | 2017-05-30 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of ATR kinase |
US10815239B2 (en) | 2013-12-06 | 2020-10-27 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of ATR kinase |
US11485739B2 (en) | 2013-12-06 | 2022-11-01 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of ATR kinase |
US10160760B2 (en) | 2013-12-06 | 2018-12-25 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of ATR kinase |
US10093676B2 (en) | 2014-06-05 | 2018-10-09 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of ATR kinase |
US9670215B2 (en) | 2014-06-05 | 2017-06-06 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of ATR kinase |
US10800781B2 (en) | 2014-06-05 | 2020-10-13 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of ATR kinase |
US11179394B2 (en) | 2014-06-17 | 2021-11-23 | Vertex Pharmaceuticals Incorporated | Method for treating cancer using a combination of Chk1 and ATR inhibitors |
US11464774B2 (en) | 2015-09-30 | 2022-10-11 | Vertex Pharmaceuticals Incorporated | Method for treating cancer using a combination of DNA damaging agents and ATR inhibitors |
US11926616B2 (en) | 2018-03-08 | 2024-03-12 | Incyte Corporation | Aminopyrazine diol compounds as PI3K-γ inhibitors |
US11046658B2 (en) | 2018-07-02 | 2021-06-29 | Incyte Corporation | Aminopyrazine derivatives as PI3K-γ inhibitors |
Also Published As
Publication number | Publication date |
---|---|
GB0619342D0 (en) | 2006-11-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2008038010A1 (en) | Pyrazine derivatives and their use in therapy | |
KR101211514B1 (en) | Azole-based kinase inhibitors | |
JP5406725B2 (en) | Compounds useful as protein kinase inhibitors | |
JP5424256B2 (en) | Derivatives of azabicyclooctane, process for producing the same and use thereof as inhibitors of dipeptidyl peptidase IV | |
KR102401743B1 (en) | Phenyl propanamide derivative, method for preparing same, and method for pharmaceutical use thereof | |
BR112015021888B1 (en) | DNA-PK INHIBITORS, THEIR USES AND PHARMACEUTICAL COMPOSITION | |
KR20150008406A (en) | Benzamide derivatives for inhibiting the activity of abl1, abl2 and bcr-abl1 | |
EP3553057B1 (en) | (hetero)arylamide compound for inhibiting protein kinase activity | |
JP2011526295A (en) | 5- and 6-membered heterocyclic compounds | |
JP2008534597A (en) | Pyridine derivatives useful as inhibitors of PKC-θ | |
CN113474346A (en) | Composition for inhibiting ubiquitin-specific protease 1 | |
KR20210072791A (en) | Fused pyrroline acting as inhibitor of ubiquitin-specific protease 30 (USP30) | |
EP2758058B1 (en) | Substituted pyrimidines | |
KR20210032430A (en) | Dimeric immune-modulating compounds for cerebloon-based mechanisms | |
US10584116B2 (en) | Heterocyclic sulfonamide derivative and medicine containing same | |
CN114163444B (en) | Chimeric compound for androgen receptor protein targeted degradation, preparation method and medical application thereof | |
CA2766056A1 (en) | Substituted 4-hydroxypyrimidine-5-carboxamides | |
WO2008038011A1 (en) | Pyrimidine derivatives as aurora a and aurora b inhibitors | |
EP3553056B1 (en) | (hetero)arylamide compound for inhibiting protein kinase activity | |
EP1764362A1 (en) | Biaryl derivatives | |
EP4069692A1 (en) | N-(3-(5-(pyrimidin-4-yl)thiazol-4-yl)phenyl)sulfonamide compounds and their uses as braf inhibitors | |
CN112442105A (en) | Novel pyrimido [4,5-d ] pyrimidin-2-one derivatives as protein kinase inhibitors | |
US20170247336A1 (en) | Substituted pyrimidines as inhibitors of hif prolyl hydroxylase | |
CN113493439B (en) | Substituted acrylamide derivative, composition and application thereof | |
US20220213086A1 (en) | Azole compounds as irak inhibitors, preparation methods and medicinal uses thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 07823948 Country of ref document: EP Kind code of ref document: A1 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 07823948 Country of ref document: EP Kind code of ref document: A1 |